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ABSTRACT 
EFFECT OF ESTROGEN ON APOPTOTIC REGULATORY MECHANISMS 
IN MESENCHYMAL STEM CELL MAINTENANCE 
 
 
Ece Terzioğlu 
M.S. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. K. Can Akçalı 
September, 91 Pages 
 
Mesenchymal Stem Cells (MSCs) can both self-renew and differentiate into fat, 
bone, cartilage, and muscle. They have a high therapeutic value due to their 
differentiation potential and nonimmunogenic characteristics, however their rareness 
and duration of their culture are the main handicaps in their application in cell-based 
therapies. Therefore, our aim was to explore the possible mechanisms that are 
involved in MSC maintenance and proliferation by using rat MSCs as a model. We 
studied the effect of estrogen on MSCs due to its role in growth regulation, 
differentiation, and cellular proliferation. In MSCs isolated from both normal and 
ovariectomized animals, the number and the CFU activity were increased when 
cultured with estrogen. To reveal the mechanism of the action of estrogen on MSC 
maintenance, we investigated the apoptotic pathway since estrogen has been shown 
to have a detrimental effect on apoptosis in other systems. The number of apoptotic 
cells decreased when MSCs were cultured in the presence of estrogen. To elucidate 
the molecular mechanism of estrogen’s effect on MSC apoptosis, we examined the 
expression of the bcl-2 family of genes. The expression of anti- apoptotic Bcl-2 and 
Bcl-xL proteins increased in the presence of estrogen, whereas the expression of pro-
apoptotic Bak decreased. Our results clearly show that estrogen increases the number 
of the functional MSCs by differentially regulating the expression of the bcl-2 family 
of genes and inhibiting apoptosis. Therefore estrogen treatment of MSCs may offer a 
potential to increase the number of MSC for treatments. 
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ÖZET 
ÖSTROJEN HORMONUNUN APOPTOZ YOLAKLARI ARACILIĞIYLA 
MEZENKİMAL KÖK HÜCRELERİNİN MUHAFAZA EDİLMELERİNDEKİ 
ETKİSİ 
 
 
Ece Terzioğlu 
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Yard. Doç. Dr. K. Can Akçalı 
Eylül 2006, 91 Sayfa 
 
 
Mezenkimal Kök Hücreler (MKH), kendilerini yenileyebilmelerinin yanı sıra yağ, 
kemik, kıkırdak, ve kas hücrelerine farklılaşabilmektedirler. Farklı hücre tiplerine 
dönüşebilme kapasitelerinin yanı sıra alıcıda reddedilme sorunu olmaması, MKH’leri 
birçok hastalığın tedavisinde bir umut haline getirmiştir. Ancak sayıca az olmaları ve 
elde edilmelerindeki uzun süreç, MKH kullanılarak yapılacak olan hücre temelli 
tedavilere engel oluşturmaktadır. Bu sebeple amacımız MKH’lerin çoğalmaları ve 
muhafaza edilmelerindeki ana mekanizmaları, sıçan MKH’lerini model olarak 
kullanarak araştırmaktı. Östrojenin farklılaşmadaki, büyümedeki ve çoğalma 
kapasitesi üzerindeki etkisi göz önüne alınarak, MKH’ler üzerindeki rolü araştırıldı. 
Normal ve yumurtalıkları alınmış sıçanların MKH’lerinin sayılarının ve koloni 
oluşturma özelliklerinin bulundukları hücre kültürü ortamına östrojen eklenmesiyle 
beraber her 2 grupta da arttığı görüldü. Östrojenin MKH’lerin çoğalma katsayılarına 
etki eden mekanizmasını bulmak amacıyla, diğer sistemlerde östrojenin etkilediği 
bilinen apoptoz yolakları araştırmaya alındı. Apoptoza uğrayan MKH’lerin hem 
normal hem de yumurtalıkları alınmış gruplarda östrojen eklenmesiyle azaldığı 
gözlemlendi. Östrojenin MKH’ler üzerindeki etkisini sağlayan moleküler 
mekanizmayı açıklamak amacıyla östrojenin etkilediği bir molekül grubu olan bcl-2 
gen ailesi üyelerinin ifadesi incelendi. Anti-apoptotik Bcl-2 ve Bcl-xL proteinlerinin 
ifadeleri östrojenin varlığında artarken pro-apoptotik Bak proteininin ifadesi azaldı. 
Sonuçlarımıza göre östrojen, fonksiyonel MKH’lerin sayılarını bcl-2 gen ailesi 
üyelerinin ifadelerini düzenleyerek ve apoptozu engelleyerek artırmaktadır. Bu 
sebeple MKH’lerin östrojene maruz bırakılması, onların olası tedavilerde 
kullanılmaları açısından önemli bir potansiyel oluşturmaktadır.   
 
Anahtar Kelimler: Mezenkimal Kök Hücreler, östrojen, bcl-2 gen ailesi, sıçan 
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1. INTRODUCTION 
 
In the last century, the lifespan of humans has increased due to better life 
conditions. Advanced technology led to progressive research results for improved 
clinical applications and treatments. This longer life phenomenon has brought 
together the concept of a better life quality, since the body functions and health 
conditions decline with time. The recent research areas mainly focus on different 
intrinsic and extrinsic factors, which might help in the treatments of diseases and 
disorders which are results of a longer life time; such as cancer, osteoporosis, stroke 
and heart attack, in addition to neurodegenerative diseases like Parkinson’s disease. 
In this respect, estrogen which is one of the most crucial hormones 
influencing the life quality of both men and women is a strong candidate in the 
maintenance of life standards. It is mainly responsible for female sexual features 
such as breast development and the menstrual cycle, but it is also involved in the 
regulation of several other mechanisms. Estrogen has an important effect on blood 
vessels, neurotransmitter systems and other aspects of the central nervous system 
(http://www.isoflavones.info/estrogen.php), sexual behaviour, bone structure, 
cognitive function (Simpson, 2003), and spermatogenesis (Simpson et al, 1999). 
When the estrogen levels decrease and menopause starts in women, osteoporosis and 
arteriosclerosis become the main problems due to estrogen’s role in bone 
mineralization and prevention of osteoporosis. After menopause, osteoporosis is 
more common in women than in men. Estrogen also decreases the possibility of 
becoming an Alzheimer’s patient (Yaffe et al, 1998). Alzheimer’s disease incidence 
is greater among women than among men mainly due to the decrease in the levels of 
estrogen after menopause (Simpson et al, 1999). Coronary heart disease increases 
double to threefold in women after menopause and it increases even more in case of 
the removal of ovaries prior to menopause (Skafar et al., 1997). These data drive 
attention to the importance of estrogen and due to this reason doctors tend to 
prescribe hormone based products as therapies for menopause 
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(http://www.isoflavones.info/estrogen.php). This indicates that estrogen has a 
physiologic significance throughout adult life and our understanding of its 
importance should not be limited only to the reproduction system.  
Stem cells, which are an evolving research topic, are another future hope for 
therapeutic applications. They are important for living organisms since they carry a 
potential for differentiating into a wide variety of cells under certain circumstances. 
Stem cells give rise to multiple specialized cell types which make up the heart, lung, 
skin, and other tissues; besides replacing cells that are damaged 
(http://stemcells.nih.gov). Stem cells can also be used in regenerative medicine, gene 
therapy, tissue repair, and patient specific stem cell therapy (Ivanova et al, 2002). 
There are many disorders, injuries, and diseases which can be cured or at least has 
the potential to be cured by the use of stem cells; such as Alzheimer’s disease, spinal 
cord injuries, Parkinson’s disease, diabetes, Huntington’s disease, and different types 
of cancer (Fuchs et al, 2004). Each day new discoveries are being made on the 
subject.  
Estrogen and stem cells, both being key factors in the preservation of life 
standards, are related with each other. Considering the protective effect of estrogen 
against severe heart, bone, and neuronal diseases combined with the refining and 
repairing characteristics of stem cells; they are future promise for many diseases. To 
understand the mechanism of their interaction is vital for obtaining the maximum 
efficiency from this collaboration. Apoptotic pathways, which are conserved 
throughout evolution, are strong candidates for this cooperation due to their estrogen 
responsive genes and their role in stem cell maintenance.  
In this context, first stem cells will be explained with their features, types, and 
importance. Then the next part of the thesis will be based on cell death, apoptosis, 
and their mechanism of regulation. Finally estrogen will be explained together with 
its effects on stem cells, apoptotic molecules, and its role in regulating stem cell 
maintenance. Particularly MSCs which are vital in the formation of several tissues 
will be focused on, and their regulation through estrogen via pro-apoptotic and anti-
apoptotic protein families will be defined.               
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1.1. Stem Cells 
 Stem cells are unspecialized cells which are capable of self-renewal and give 
rise to differentiated cells (Till and Mcculloch 1961). It is still not clear how they 
remain undifferentiated in their microenvironment. The internal signals which are 
regulated by genes, and the external signals which consist of secreted factors, and 
interactions among cells are the main factors stimulating the differentiation of stem 
cells. They are found in various sources such as the embryo, bone marrow, blood, 
cornea and retina of the eye, brain, skeletal muscle, dental pulp, liver, skin, lining of 
the gastrointestinal tract, and pancreas. Although self-renewal and differentiation to 
other cells are their common features; stem cells vary in their potential to 
differentiate, duration and pathways of self-renewal, places they are mostly found in, 
and division properties (Morrison et al, 1997).  
 Stem cells can be classified due to their source of origin and their potential to 
differentiate to different cell types. There are three main types of stem cells: ESCs, 
GSCs, and ASCs. When the oocyte is fertilized, it becomes a zygote which has the 
capacity to give rise to the embryo and extraembryonic membranes. The zygote is 
the only totipotent cell, which can differentiate to any type of cell and form the 
embryo. When the embryo becomes 4-5 days old, ESCs are derived from the inner 
cell mass of the embryo (Brook and Gardner, 1997). They are pluripotent and can 
give rise to cells from all three germ layers: endoderm, mesoderm, ectoderm 
(Thomson et al, 1998). GSCs are found in the gonadal ridge of the 5 -10 week fetus 
as primordial germ cells. They are pluripotent when cultured in vitro and form EGCs 
(Xi et al, 2005). ASCs on the other hand are found in specific tissues and organs. 
They are multipotent and give rise to more than a single cell type but are not capable 
of differentiating into tissues of all germ-layers (Figure 1.1) (Serakinci and Keith, 
2006).  
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Figure 1.1 The differentiation of cells from the zygote (http://stemcells.nih.gov) 
 
1.1.1. Embryonic Stem Cells 
 
ESCs were first isolated from the inner cell mass of the mouse in 1981 by 
Kaufman and Martin, and from humans in 1998 by Thomson et al. ESCs are not 
embryos themselves but they can form cells from all three germ-layers and undergo 
an unlimited number of symmetrical divisions without differentiating in vitro 
(Burdon et al, 2002). In order to generate cultures of mouse and human ESCs, the 
inner cell mass is removed from the trophectoderm and is transferred to the top of 
MEFs on the culture medium. These MEFs which are called feeder layer are 
inactivated so that they can not divide, but they provide a sticky surface for the ESCs 
to attach besides releasing essential factors to the culture medium. Both mouse ESCs 
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and human ESCs can be grown both with and without a feeder layer (Xu et al, 2001; 
Reunbinoff et al, 2000). A single ESC can give rise to a colony of genetically 
identical cells, or clones under appropriate conditions (Sell, 2003) (Figure 1.2).  
 
 
 
 
Figure 1.2 Tissue culture methods of ESCs (http://stemcells.nih.gov/) 
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ESCs can stay undifferentiated for a long period of time in vitro, and there are 
several examples to prove the pluripotentiality of ESCs. When mouse ESCs derived 
from one blastocyst are injected to another blastocyst and is transferred to the uterus 
of a pseudopregnant mouse in vivo, chimeras form which are a mixture of tissues and 
organs derived both from the host and the donor blastocyst (Prelle et al, 1999). Also 
when ESCs are injected into adult immune-deficient mice, they develop into tumors 
called teratomas which contain cells from all three germ layers (Martin, 1981). In 
vitro when the culture conditions are changed, ESCs form embryoid bodies (EB) 
which have a similar structure to teratomas. They form large structures which contain 
partially differentiated cells from all three germ layers in a disorganized manner 
(Evans and Kaufman, 1981). Both mouse and human ESCs express oct-4 which is an 
important gene in the maintenance of pluripotency. Also with the induction of certain 
growth factors, ESCs differentiate into different types of cells. In order to induce 
ectodermally derived cells: retinoic acid, EGF, BMP4, and bFGF are added; to 
induce mesodermally derived cells: activin-A, and TGF-ß1 are added; and in order to 
induce differentiation into all three germ layers including the endoderm: HGF, and 
NGF are added to culture (Bishop et al, 2002). These indicate that ESCs are 
pluripotent and have the potential of contributing to the formation of cells from all 
germ layers both in vitro and in vivo. 
ESCs also have high telomerase activity, which adds telomere repeats to the 
ends of chromosomes resulting in long telomeres (Armstrong et al, 2000; Xu et al, 
2001). They have stable karyotypes, and X inactivation does not occur in the 
undifferentiated ESCs (Reunbinoff et al, 2000). Unlike differentiated cells, ESCs do 
not require any external stimulus in order to initiate DNA replication. ESCs lack the 
G1 checkpoint in the cell cycle and spend most of their time in the S phase of the cell 
cycle synthesizing DNA. When they start to differentiate, the G1 phase of the cell 
cycle becomes longer with the increase in Cyclin D expression and the rate of cell 
division slows (Burdon et al, 2002).   
ESCs can be used in several ways in basic and clinical research. Studies on 
ESCs are very informative on the complex events that occur during human 
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development. Understanding the genetic and molecular control mechanisms behind 
the stem cell regulation may provide an understanding on how genetic and growth 
abnormalities arise and suggest new strategies and methods for their therapy.  
In addition to all the positive aspects of ESCs, there are several handicaps in 
their research and applications. Since there are many different cellular pathways 
regulating them, it is hard to figure out the interactions between them. ESCs can not 
give rise to a full embryo but the fact that they are isolated from embryos creates 
problems, therefore there are ethical problems arising. In addition, when injected to 
immunodeficient mice, they form tumors. This indicates that due to their high 
differentiation potential, they can form any type of cell so they have to be controlled 
very strictly and all the factors affecting the differentiation of ESCs should be figured 
out before using them in any clinical application. Also ESCs have a potential to 
cause immune rejection, which is another obstacle. Until the big gaps are filled in the 
area of stem cell regulation and differentiation besides the ethical issues being 
solved, ESCs can not be used in therapeutic applications.      
1.1.2. Embryonic Germ Cells 
 
EGCs were first identified in 1998 by John Gearheart and they were cultured 
from PGCs obtained from the gonadal ridge and mesentery of the 5th to 9th week of 
fetal tissue (Figure 1.3). They are pluripotent cells and express oct-4 besides other 
pluripotency markers similar to ESCs, and they have the capacity for long-term self-
renewal. In addition they have a normal stable karyotype (Shamblott et al, 1998). 
The location and maintenance of germ-line stem cells are among the most studied 
areas and are clearly identified. Especially Drosophila is the best studied model in 
this area both in male and in female (Gilboa and Lehmann, 2004).    
 
 8 
 
Figure 1.3 The role of primordial germ cells in life cycle 
(http://stemcells.nih.gov/info/scireport/appendixA.asp) 
 
PGCs are diploid germ cell precursors which transiently exist in the embryo 
before they are committed as germ cells. In order to obtain EGCs, PGC cultures are 
grown in fetal bovine serum supplemented media. The PGCs are plated on a feeder 
layer consisting of STO fibroblasts which are non-dividing. They are cultured in a 
growth medium which includes the cytokine, LIF, bFGF, and forskolin. At the end of 
three weeks, the PGCs form dense, multilayered colonies of cells resembling EGCs. 
Although both are pluripotent, cultures derived from embryoid bodies generated 
from human EGCs have less capacity for proliferation compared to ESCs. EGCs will 
proliferate for 40 population doublings while human ESCs can proliferate for two 
years through 300 population doublings or even 450 population doublings. Another 
major difference between the pluripotency of ESC and EGC is that EGC do not form 
teratomas when injected to immunodeficient mouse (Pedersen, 1999).  
 Although both are pluripotent, EGCs do not have the same proliferation and 
differentiation capacity as ESCs do, which makes EGCs less appealing for 
therapeutic applications. Also they do not form teratomas when injected to 
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immunosuppressed mouse, and they do not participate in the formation of chimeras 
in viv0; which suggest that EGC’s differentiation potential is not as wide as ESC’s 
(Shamblott et al, 1998). In addition there is not much known about their telomerase 
activity either, which might be a reason why their doublings are shorter than ESCs 
(http://stemcells.nih.gov/).   
 
1.1.3. Adult Stem Cells 
 
In the pioneering experiments with ASCs in 1940-1950’s, the researchers 
were able to repopulate the blood cells of a mouse by the infusion of bone marrow 
cells from a different mouse. In 1960; two different kinds of stem cell population 
have been identified in the bone marrow; hematopoietic stem cells (HSCs) which 
form all types of blood cells and bone marrow stromal cells which generate bone, 
cartilage, fat, and fibrous connective tissue. In the 1990’s neural stem cells were 
discovered which are able to generate the brain's three major cell types: astrocytes, 
oligodendrocytes, and neurons. 
ASCs are found in tissues and organs, and their primary role is to maintain 
homeostasis. They are important for the organ or tissue to fulfill their required task 
besides supplying them with the sufficient amount of stem cells for a life-time 
(Serakinci and Keith, 2006). ASCs are mostly found in the bone marrow, blood, 
cornea and retina of the eye, brain, skeletal muscle, dental pulp, liver, skin, the lining 
of the gastrointestinal tract, and pancreas. They usually divide to generate progenitor 
or precursor cells, which then give rise to specialized cells with specific shapes and 
functions (Weissman, 2000).  
The number of ASCs is rare compared to other types of cells and they do not 
divide very often unless there is a stimulus such as tissue injuries or diseases. ASCs 
are scattered throughout the tissues of the mature organism and have very different 
roles depending on their local environment. Currently, cell surface markers and 
observations on stem cell differentiation patterns in test tubes and culture dishes are 
being used for the characterization of adult stem cells. It is also hard to expand ASCs 
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in culture in an undifferentiated state. Many factors including growth factors, 
extracellular matrix contacts, cell-cell interactions, and intrinsic cell kinetics 
(Sherley, 2002) effect their maintenance and differentiation.  
Most of the ASCs are stored in specific cell compartments called niches, 
which are the microenvironments where ASCs are located with the same type of 
stem cells and differentiated cell types. These niches provide an extracellular matrix, 
adherens junctions, and integrins besides allowing physical interactions between 
cells. This enables stem cells to stay in an undifferentiated state and give rise to 
differentiated cell types when necessary. Niches are crucial by means of affecting the 
properties of stem cells but are not irreversible. They are also effective in the 
determination of symmetric division (Fuchs et al, 2004). In addition to differentiating 
into cells which they are programmed to, ASCs may also form the specialized cell 
types of other germlayers, which is known as plasticity (Horwitz, 2003). If the 
mechanisms beneath adult stem cell plasticity can be identified and controlled, 
existing stem cells from different sources might be used in the repair of diseased 
tissues and cells of other origins.   
 The most commonly studied ASCs are HSCs, MSCs, neural stem cells, 
epithelial stem cells, and skin stem cells. HSCs give rise to red blood cells, B 
lymphocytes, T lymphocytes, natural killer cells, neutrophils, basophils, eosinophils, 
monocytes, macrophages, and platelets. MSCs give rise to osteocytes, chondrocytes, 
adipocytes, and other kinds of connective tissue cells such as those in tendons. 
Neural stem cells in the brain give rise to three major cell types: nerve cells (neurons) 
and two categories of non-neuronal cells: astrocytes and oligodendrocytes. Epithelial 
stem cells in the lining of the digestive tract give rise to absorptive cells, goblet cells, 
paneth cells, and enteroendocrine cells. Skin stem cells are found in the basal layer of 
the epidermis and at the base of hair follicles. They give rise to keratinocytes, hair 
follicle, and epidermis (http://stemcells.nih.gov/).  
ASCs can be used in the generation of cells and tissues in cell-based 
therapies. The organs and tissues donated are often used to replace malfunctioning or 
destroyed tissues, but the need for transplantable tissues and organs is a lot more 
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compared to the available supply. ASCs offer the possibility of a renewable source 
for replacement of  cells and tissues to treat several diseases. ASCs are potential 
future treatments for various diseases such as cardiac disorders, diabetes, Alzheimer 
disease and many others (http://stemcells.nih.gov/). 
On the other hand there are still many unknowns and questions to be 
answered such as how they stay undifferentiated in a differentiated environment, the 
signals regulating their differentiation and proliferation, the stimuli leading them to 
sites of injury, and how they can be increased in number in order to reach an 
adequate number to heal injuries. In addition, due to the large set of unknowns in this 
area, it is hard to identify, isolate, and maintain ASCs (Badge, 2001). Also there are 
big gaps in the detection of the differentiation factors affecting their specialization, 
which prevent the in vitro tissue and organ synthesis. Mainly, the signals affecting 
ASC self-renewal and differentiation should be revealed in order to consider ASCs 
for possible treatments.   
 
1.1.3.1 Mesenchymal Stem Cells 
 
 MSCs are adult stem cells mostly found in the stromal part of the bone 
marrow. They were first identified in 1966 by Friedenstein and Patrakova by the 
isolation of bone-forming progenitor cells from the rat bone marrow (Barry and 
Murphy, 2004). They can self-renew as all stem cells do, and have a multilineage 
differentiation potential. They can differentiate into osteoblasts, chondrocytes, and 
adipocytes, myocytes which form the bone, cartilage, tendon, muscle, and fat. They 
are thought to differentiate into certain types of endodermal and ectodermal tissues 
as well such as neurons and endothelial cells. In addition they are a part of the 
hematopoietic stem cell niche (Figure 1.4) (Baksh et al, 2004; Caplan and Bruder, 
2001).  
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Figure 1.4 The differentiation of MSCs (Raghunath et al, 2005) 
 
Although the main source of MSCs is the bone marrow, they can be isolated 
from other sources as well such as the trabecular bone (Noth et al, 2002), adipose 
tissue, synovium, skeletal muscle, lung, placenta, deciduous teeth (Tuan et al, 2003), 
human umbilical cord perivascular cells (Sarugaser et al, 2004), and periosteum 
(Minguell et al, 2001). Among the MSCs obtained from different sources, there is 
not much difference by means of yield, growth kinetics, cell senescence, multi-
lineage differentiation capacity, and gene transduction capacity (De Ugarte et al, 
2003). Although it is known that MSCs exist in many sources, their niche and the 
structure of their niche is not clear. HSC and MSC niche can be thought to be the 
same since both of them are found mostly in the bone marrow, but this is not the case 
because they are very different from each other and need to remain in different 
environments with different signals in order to stay undifferentiated. Also MSCs are 
found in many different sources, so the niches of HSCs and MSCs have to be 
different (Baksh et al, 2004).    
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 MSCs are studied in various model organisms such as human, canine, rabbit, 
rat, and mouse and it is shown that MSCs isolated mostly from the bone marrow 
differentiate to different types of cells both in vitro and in vivo (Barry and Murphy, 
2004). The MSC isolation from every animal is from different sites of the bone 
marrow using different methods. In humans it is mostly from the pelvis (Digirolamo 
et al, 1999), tibia and femur. In larger animals it is from the same site but in rodents 
it is usually harvested from the mid-diaphysis of the tibia and femur (Barry and 
Murphy, 2004).  
MSCs are a very small fraction of the nucleated cells in the bone marrow; 
only %0.01- %0.1 of the total population (Pittenger et al, 1999). They can be isolated 
and expanded in tissue culture conditions with high efficiency and they can be 
induced to differentiate under specific conditions. They have fibroblastic 
morphology and they are adherent spindle-shaped cells. Under appropriate media 
conditions, MSCs adhere to the culture plate leading to the formation of colonies. 
Usually basal mediums with serum support are used to expend MSCs in tissue 
culture and growth factors are added in order for MSCs to differentiate (Barry and 
Murphy, 2004)  
MSCs have a highly variable expansive potential in subculturing. Some MSC 
cultures can expand more than fifteen cell doublings, while others can replicate only 
about four cell doublings. There are several reasons for this difference such as the 
procedure to harvest the marrow, the low frequency of MSCs in marrow harvests, 
and the age or condition of the donor. Although MSCs have a high ex vivo expansion 
potential, they do not loose their normal karyotype and telomerase activity. However, 
in extensive subcultivation, signs of senescence and apoptosis are observed 
(Minguell et al, 2001).  
There is no in vivo marker to distinguish MSCs from other cell types but in 
vitro STRO-1 (Minguell et al, 2001), SB-1, SH2, SH3, SH4 (Baksh et al, 2004) 
identify MSCs in humans and CD71, CD90, CD106, and CD117 identify them in 
rodents (Mangi et al, 2003). In general, it is hard to find specific markers for MSCs 
since they have common characteristics with other types of cells such as endothelia, 
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epithelial cells, and muscle cells. It is known though that they do not express CD45, 
CD34, and CD14 which are HSC markers (Baksh et al, 2004), and they mostly 
express a large spectrum of cell adhesion molecules which are important for cell 
binding and homing such as integrin markers alpha1, alpha5, and beta1 (Barry and 
Murphy, 2004).      
 Although MSCs might be thought as a homogeneous population which has a 
multilineage potential, they are a very heterogeneous population due to the complex 
regulatory mechanisms which are not fully revealed at the moment. Only a small 
proportion of MSCs are actively proliferating, and approximately 10% of them are at 
S + G2 + M stages. However the majority of them are at the Go/G1 phase of the cell 
cycle, which suggests that MSCs have a high potential to differentiate (Conget and 
Minguell, 1999). There are many molecules taking part in MSC regulation such as 
cytokines, growth factors, adhesion molecules, and extracellular matrix components 
(Kratchmarova et al, 2005). The master switches regulating the transitions from stem 
cells to differentiated cells, and the genes active in specific differentiation patterns 
are still not known. The reason for the difficulty to find these regulatory genes is 
their temporal activity, the reaction given to inductive molecules, and the varying 
differentiation pathways between organisms (Baksh et al, 2004; Caplan et al, 2001). 
MSC markers and colony forming assay are accepted currently to be sufficient to 
identify MSCs. 
 MSCs are already used in therapies for osteogenesis imperfecta, 
hematopoietic recovery, bone tissue regeneration (Baksh et al, 2004), cardiovascular 
repair, treatment of lung fibrosis, spinal cord injury, coronary artery disease 
(Minguell et al, 2001), local repair, and regeneration of bone cartilage and tendon. 
They can form intervertebral disc cartilage, bone, cardiomyocytes, articular cartilage 
at knee joints, besides neurons, skin epithelia, lung, liver, kidney, intestine, and 
spleen (Figure 1.5) (Baksh et al, 2004).   
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Figure 1.5 The differentiation and plasticity of MSC (Minguell et al, 2001) 
 
Aside from their differentiation potential and immunesuppression, there are 
other aspects which make MSCs valuable for therapeutics. MSCs actively inhibit T-
cell proliferation and due to this reason they are considered as nonimmunogenic or 
hypoimmunogenic which is important in host response to allogeneic MSC therapy. 
The only problem of this aspect is a potential disease transmission from donor to 
recipient. Another important feature of MSCs is long-term homing and engraftment 
of implanted cells to various tissues even after the development of 
immunocompetence. The implanted MSCs can migrate to the specific site of injury 
by the help of factors that are released from the wound. This has been observed in 
cases like bone fractures, myocardial infarction, meniscus, and ischemic cerebral 
injury. Also at specific sites it has been observed that the stem cells injected 
differentiate according to the local signals at the local site of injury (Miguell et al, 
2001). MSCs have a high potential for regenerative medicine and tissue engineering 
besides being used as a gene delivery method, which makes their therapeutic value 
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very high. Researchers are looking for different ways to use specialized cells derived 
from MSCs in targeting specific cancerous cells and delivering treatments that will 
destroy them or make them benign. 
Besides these advantages of MSC in therapeutic applications, there are some 
unknowns like long-term effect and safety which require more toxicology studies. In 
addition, the efficiency is not clear. There are some evidences on homing and 
differentiation, but they are insufficient. Also large-scale culture, storage and 
distribution are important for their applications of MSCs (Miguell et al, 2001).     
 
1.2. Cell Death and Apoptosis 
 
Cell death occurs through two main pathways: necrosis which is accidental 
cell death and apoptosis which is programmed cell death. These two pathways vary 
by means of their morphological and biochemical features besides the stimuli to 
induce them. Necrosis is non-programmed cell death which occurs abruptly when the 
cell is damaged. The cells swell, organelles dissolve, the plasma membrane ruptures, 
and the cytoplasmic content gets released which causes an inflammatory response 
(Desagher and Martinou, 2000). Apoptosis on the other hand, is a gradual and 
programmed cell death. The cells undergo morphological changes such as nuclear 
and cytoplasmic hypercondensation, cell shrinkage, plasma membrane blebbing, 
DNA fragmentation, and cleavage of chromosomes into nucleosomes. Apoptotic 
bodies form at the end of this process which contains components of dying cell and 
are removed by phagocytosis preventing the release of cytoplasmic and nuclear 
components to the extracellular space (Desagher and Martinou, 2000; Shi, 2001). 
Apoptosis is crucial for homeostasis and is involved in the regulation of several 
pathways.   
 
1.2.1. Apoptosis and its Evolutionary Conservation 
 
 Apoptosis is a cell suicide mechanism which enables organisms to keep their 
cell number under control and eliminate the cells which have deficiencies such as 
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genetic defaults or threaten the organism’s survival (Ashkenazi and Dixit, 1998). It 
can be triggered by external and internal death signals and it participates in diverse 
mechanisms such as embryonic development, tissue morphology determination, and 
creation of the neural and vascular network. The regulation of apoptosis is 
complicated and since it is conserved throughout evolution, is preserved very strictly. 
Any disruption in the apoptotic pathways cause many disorders such as autoimmune 
diseases, neurodegenerative diseases like Alzheimer’s disease, cancer, viral 
infections, osteoporosis, and AIDS (Green and Martin, 1995; Thompson, 1995).  
 The apoptotic regulation pathway was first discovered in the nematode 
Caenorhabditis Elegans (Ellis and Horvitz, 1986). The apoptotic interactions cause 
the death of approximately 131 cells out of 1090 somatic cells at different times and 
different locations during the development of C. Elegans (Steller, 1995). The main 
apoptotic genes in C. Elegans are ced4, ced3, and ced9. CED-4 binds to CED-3 
promoting the activation of CED-3, while CED-9 binds to CED-4 inhibiting the 
activation of CED-3 (Hengartner and Horvitz, 1994). Under normal conditions CED-
9 stays bound to CED-4 keeping CED-3 inactive, but apoptotic stimuli cause CED-9 
to dissociate by EGL-1 which allows the activation of CED-3 leading to apoptosis 
(Shi, 2001). A similar system also exists in other organisms. The mammalian 
homolog of CED-4 is Apaf-1, CED-3 is Caspase 3, Bid and Bcl-2, which are 
members of Bcl-2 family of proteins are similar to CED-9 and EGL-1 (Figure 1.6) 
(Zou et al, 1997; Shi, 2001).       
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Figure 1.6 The conservation of the apoptotic mechanisms between species (Shi, 
2001) 
 
1.2.2. Regulation of Apoptosis  
 
Since apoptosis takes part in such a variety of physiological and non-
physiological conditions, understanding the molecular mechanism of the regulation 
of apoptosis is important. Apoptosis can be induced by either intrinsic pathways 
which are activated as a result of intracellular stress like DNA damage, or extrinsic 
pathways which are triggered by extracellular factors acting on the death receptors 
such as Fas and TNFR-1 (Shi, 2001). In the intrinsic or mitochondrial pathway; 
cytochrome c is released, apoptosome which consists of cytochrome c is formed, and 
APAF1, pro-caspase-9, and caspase-9 are activated. Endoplasmic reticulum stress 
triggers the ER-specific pathway which results in the activation of caspase-12 in 
mice or caspase-4, and caspase-3 or caspase-7 in humans. Extrinsic pathways are 
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activated by extracellular ligand binding to death receptors and results in either 
caspase activation or need further amplification through the mitochondrial pathway, 
according to the cell type. Fas and TNFR1 can be given as examples of the most 
commonly studied death receptors. (Figure 1.7) (Holcik and Sonenberg, 2005; Liston 
et al, 2003; Gebauer and Hentze, 2004; Ashkenazi and Dixit, 1998) 
 
 
 
Figure 1.7 Different mediations of the apoptotic pathways (Holcik and 
Sonenberg, 2005) 
 
1.2.2.1. Mitochondrial Apoptosis 
 
Mitochondrial apoptosis which is also the intrinsic pathway, is crucial for 
homeostasis and animal development. After receiving apoptotic stimuli, cytochrome 
c is released to the cytoplasm from the intermembrane space of mitochondria. The 
release of cytochrome c triggers the activation of a specific set of proteins called 
caspases. Caspases are a group of cysteine proteases which cleave selected proteins 
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at their aspartate residues. Fourteen caspases are identified in mammals and at least 
eight of them have critical roles in apoptotic regulation (Budihardjo et al, 1999). 
Caspases are categorized as the initiator caspases (caspase-2, caspase-8, caspase-9, 
caspase-10), and the effector caspases (caspase-3, caspase-6, caspase-7). The effector 
caspases are activated by initiator caspases while initiator caspases activate 
themselves. Initiator caspases are strictly regulated requiring an assembly of 
multicomponent complex since they activate a downstream of caspases. Caspase 
activity is inhibited by the conserved IAP family of proteins. Eight different 
mammalian IAPs which include XIAP, c-IAP1, c-IAP2, and ML-IAP/Livin have 
been identified (Shi, 2002). They target caspase-9, caspase-3 and caspase-7 but not 
other caspases (Holcik and Sonenberg, 2005). 
After the release of cytochrome c from mitochondria, it binds to Apaf-1 and 
activates it by changing its confirmation (Jiang and Wang, 2000; Purring et al, 1999). 
This complex then binds to dATP or ATP, and forms a multimeric complex which is 
called apoptosome which activates procaspase-9 (Saleh et al, 1999) After being 
activated, caspase-9 forms a holoenzyme with the apoptosome, targeting primarily 
procaspase-3 which is one of the most important effector caspases (Jiang and Wang, 
2000; Shi, 2001). Active caspase-3 cleaves a wide range of proteins including 
caspase-2, caspase-6, DFF45, DNA-dependent protein kinase, and nuclear lamin 
(Thornberry and Lazebnik, 1998). The degradation of DFF45 stops inhibiting DFF40 
(CAD), which in return degrades chromatin into nucleosomal fragments, one of the 
main characteristics of apoptosis.  
In cells which have not received any apoptotic stimuli, the enzymatic activity 
of mature caspases is inhibited by IAPs (Deveraux and Reed, 1999; Miller, 1999). 
However this inhibition must be supressed in cells which undergo apoptosis and this 
is regulated by smac also called DIABLO, which is a 25-kD mitochondrial protein 
(Verhangen et al, 2000). It is synthesized in the cytoplasm and is released together 
with cytochrome c to the cytosol upon apoptotic stimuli. While cytochrome c 
activates Apaf-1 and caspase-9, smac interacts with IAP enabling the activation of 
caspases (Verhangen et al, 2000; Chai et al, 2000). This process is regulated by the 
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Bcl-2 family members which effect cytochrome c release and apoptotic regulation 
(Adams and Cory, 1998; Adams and Cory, 2001). The importance of this pathway is 
clear by the observation that Apaf-1 is frequently inactivated in cancers such as 
malignant melanoma (Figure 1.8) (Soengas et al, 2001).    
 
 
 
 
Figure 1.8 Mitochondrial regulation of apoptosis (Wang, 2001) 
 
1.2.2.2. Bcl-2 Family of Proteins  
 
 Bcl-2 family of proteins is among the best characterized protein family which 
takes place in the regulation of apoptosis. It consists of both pro-apoptotic and anti-
apoptotic members. They function by forming homo- and heterodimers. The rate of 
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the pro-apoptotic to anti-apoptotic molecules determines the susceptibility to death 
stimuli (Chao and Korsmeyer, 1998). 
  The prototype of this family, Bcl-2, was first identified in B-cell leukemia 
cell line as an oncogene which inhibited cell death rather than promoting 
proliferation (Cory and Adams 2002, Bakhshi et al, 1985; Cleary and Sklar, 1985). 
The anti-apoptotic activity of Bcl-2 was proven first by inducing apoptosis with IL-3 
deprivation (Vaux et al, 1988) and then it was shown that Bcl-2 prevented apoptosis 
induced by several stimuli such as serum deprivation, chemotherapeutic agents, and 
heat shock (Tsujimoto, 1989). In higher eukaryotes at least 20 homologs of Bcl-2 
have been identified, sharing at least one conserved BH domain (Vaux et al, 1992; 
Hengartner and Horvitz, 1994). These can be categorized into three groups: Bcl-2 
like survival factors, Bax-like death factors, and BH-3 only death factors (Figure 
1.9). 
  
Figure 1.9 Classification of the Bcl-2 family members (Festjens, 2004) 
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 The pro-survival family consists of Bcl-2 and its closest homologs Bcl-xL, 
and Bcl-w besides Mcl-1, A1/Bfl-1, and Diva. This is a new class of proto-
oncogenes that block cell death without promoting cell proliferation and it also has a 
role in cell cycle (Conradt and Horvitz, 1998). Bcl-2 prevents cell death by inhibiting 
free radical production, suppressing caspase activation, regulating calcium 
sequestration, and by preventing the pro-apoptotic factors from inducing apoptosis 
(Merry and Korsmeyer, 1997). Bcl-2 deficient T cells show increased apoptosis 
following cell cycle progression. Bcl-2 is widely expressed during embryogenesis 
but it decreases and becomes much more restricted postnatally in the nervous system 
(Susin et al, 1996). Bcl-2 may be important in maintaining cell survival during 
interactions between epithelium and mesenchyme (Thornberry and Lazebnik, 1998; 
Tsujimoto, 1989). In addition, Bcl-2 and Bcl-xL have a reciprocal pattern of 
expression in B cell compartments. Bcl-2 itself is required for the survival of kidney 
and melanocyte stem cells and mature lymphocytes. Bcl-2 and Bcl-xL prevent 
apoptosis either by segmenting caspases or by preventing the release of 
mitochondrial apoptogenic factors such as cytochrome c and AIF into the cytoplasm. 
They contain BH domains BH1, BH2, BH3, BH4, and a hydrophobic C-terminal tail 
which functions as a membrane anchor (Janiak et al, 1994). BH1-3 form a 
hydrophobic groove, with which BH3-only death factors interact through their BH3 
domain, while the BH4 domain stabilizes this pocket (Zha et al, 1996; Luo et al, 
1998). The core three-dimensional structure is well conserved between Bcl-xL, Bcl-2, 
and Bcl-w. They are targeted to the outer mitochondrial membrane, endoplasmic 
reticulum, and nuclear envelope. It is becoming clear that every nucleated cell needs 
the protection of at least one Bcl-2 homologue, and these homologs regulate tissue 
homeostasis. Bcl-2 is required for kidney survival, melanocyte stem cells, and 
mature lymphocytes; Bcl-xL for neuronal and erythroid cells; and Bcl-w for sperm 
progenitors in adult mice (Cory and Adams, 2002).  
 The Bax-like pro-apoptotic death factors consist of Bax, Bak, and Mtd/Bok. 
These pro-apoptotic members lack the BH4 domain. The presence of either Bax or 
Bak, which are thought to function mainly at the mitochondria, seem to be crucial for 
apoptosis in many cell types since most death stimuli converge on their activation 
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(Gross et al, 1999; Vander Heiden and Thompson, 1999). They stimulate the release 
of caspases by heterodimerization and also by inducing the release of mitochondrial 
apoptogenic factors into the cytoplasm by acting on mitochondrial permeability 
transition pore, which leads to caspase activation (Tsujimoto, 1998). Bax 
heterodimerizes with Bcl-2, and homodimerizes with itself. When Bax is 
overexpressed in cells, apoptotic death in response to a death signal accelerates, but 
when Bcl-2 is overexpressed, it heterodimerizes with Bax and apoptosis is repressed 
(Kluck et al, 1997). Thus, the ratio of Bcl-2 to Bax is important in determining the 
tendency to go through apoptosis. In healthy cells Bax is a cytosolic monomer and is 
either loosely attached to the mitochondrial membrane or remains in the cytosol. 
Upon receiving death stimulus, cytosolic Bax goes through a conformational change 
and is oligomerized and translocated to the mitochondria where it becomes an 
integral membrane protein (Wolter et al, 1997). Also with the induction of the death 
stimuli the membrane associated Bax changes the exposition of its N-terminal BH3 
domain (Zong et al, 2001) whereas in the absence of death signals the N-terminal 
domain does not allow the transmembrane anchor to function. This explains the 
reason for Bax failing to insert in the mitochondrial membrane in healthy cells. In 
addition, when Bax is activated, it binds to and antagonizes anti-apoptotic Bcl-2 
proteins (Puthalakath et al, 1999). Bak on the other hand is an oligomeric integral 
mitochondrial membrane protein even in healthy cells, but changes conformation 
during apoptosis as well to form larger aggregates (Griffiths et al, 1999). The Bax-
like proteins act in mitochondrial disruption.   
 The BH-3 only group consists of Bad, Bid, Bik/Biklk, Bim, Hrk, and Bnip3. 
They have only the BH3 domain which enables dimerization and is sufficient for 
their killing (Shi, 2001). They induce apoptosis mostly in response to developmental 
signals or intracellular damage (Huang and Strasser, 2000). They are upstream 
sensors and mediators of apoptotic cell death. BH3 domains of several BH3-only 
proteins either directly activate Bax/Bak proteins or bind to the hydrophobic pocket 
of anti-apoptotic Bcl-2 family members (Letai et al, 2002). The programmed death 
of the somatic cells of C. Elegans require a single BH3-only protein, EGL-1. The 
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eight or more mammalian BH3 proteins homologs allow a more-refined control over 
cell death.  
 There are a few models on how Bcl-2 family of proteins work. In one of the 
most accepted ones Bax and Bak are responsible for the release of mitochondrial 
proteins and are negatively regulated by Bcl-2 and Bcl-xL (Korsmeyer, 2000, 
Antonsson et al, 2000). Bax forms a channel either by itself or with the help of other 
factors and in apoptotic cells this channel is responsible for the release of the proteins 
from the intermembrane space of mitochondria to the cytosol. However the binding 
of Bcl-2 to Bax closes this channel. Upon apoptotic stimuli, Bid or PUMA is 
activated and interacts with the Bcl-2 protein to relieve the inhibition of the Bax-
dominated channel. This model is in consistency with many biological and 
biochemical observations. This model also differentiates the functions of the two 
pro-apoptotic subfamilies, the BH3-only (Bid or PUMA) and the Bax-like pro-
apoptotic members. Bcl-2 family of proteins control the permeability of 
mitochondria but it is not clear whether they are the primary components of the pores 
or they regulate the open-close status of the pores. How the three subfamilies of Bcl-
2 proteins work in vivo is also unclear (Shi, 2001). In the overall picture though, the 
Bcl-2 family of proteins act as a critical life–death decision point within the common 
pathway of apoptosis.  
 
1.3. Estrogen 
 
Estrogen is a hormone which is produced by the ovaries and testes. It 
stimulates the development of secondary sexual characteristics, induces 
menstruation, and regulates growth, differentiation, cell proliferation, metabolic 
activities, reproduction, homeostasis, cardiovascular health, bone integrity, cognition, 
and behavior. It targets many organs like the brain, heart, bone, breast, uterus, and 
prostate. This wide range of organs, which estrogen is involved in the functioning of, 
makes estrogen a very important hormone for therapy and therefore it is crucial to 
understand the imbalances of estrogen, gene networks controlled by estrogen, and 
regulation of its targets (Deroo and Korach, 2006; Paech et al, 1997).  
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Estrogen regulation occurs through several different mechanisms but mostly 
it induces cellular changes through estrogen receptor (ER). ER exists in 2 forms: 
ERα and ERß which have different expression patterns according to the organism 
and organ they are found in. In this common regulation pathway estrogen diffuses to 
the cell, binds to an ER and results in the conformational change of the ER. Then this 
estrogen-ER complex binds to specific DNA sequences called estrogen response 
elements (ERE) directly or indirectly with AP1. The ligand which binds to ER makes 
a conformational change, which promotes the binding to ERE. When ERα and ERß 
form complexes with estrogen from an AP1 site, they signal in different ways 
depending on the ligand and response element, and they inhibit or activate 
transcription accordingly (Deroo and Korach, 2006; Smith and O’Maley, 2004). The 
ligand bound receptor also forms a complex with coactivator proteins which activates 
target gene expression through chromatin remodeling. This suggests that depending 
on the complex formed, ERs play different roles in gene regulation. (Weitzmann and 
Pacifici, 2006; Deroo and Korach, 2006; Paech et al, 1997). 
Estrogen exerts its effects through its target genes. Estrogen affects hundreds 
of genes in different tissues and the expression profiles of these genes change with 
developmental stages and diseases. The coordination of these genes is mainly by 
estrogen but there are also other factors like type of ER, co-regulators, estrogen 
exposure time, and estrogen amount (Deroo and Korach, 2006; Tang et al, 2004). 
The regulatory groups which these genes affect can be classified as 
cytokines/immune response, signal transduction, cell motility/cytoskeleton 
regulation, growth factors/hormones, apoptosis/cell proliferation, housekeeping, 
nucleic acid processing, and other/unknown (Stossi et al, 2004). Due to these diverse 
mechanisms, estrogen responsive genes are very crucial for research and clinical 
purposes.   
 Estrogen regulation is affected by agonists and antagonists which exhibit 
tissue-specific estrogenic activity. The same molecule might act both as an 
antagonist and an agonist depending on the organism and tissue. For example 
tamoxifen is an agonist in bone and uterus whereas it is an antagonist in breast. 
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Raloxifene resembles tamoxifen and in addition it is used in the prevention of 
osteoporosis. These estrogen receptor modulators also affect the ER signaling (Deroo 
and Korach, 2006; Paech et al, 1997).  
 A very tight correlation has been established between estrogen and several 
diseases such as breast cancer, ovarian cancer, colorectal cancer, prostate cancer, 
endometrial cancer, osteoporosis, neurodegenerative diseases, cardiovascular 
diseases, insulin resistance, lupus erythematosis, endometriosis, and obesity (Deroo 
and Korach, 2006). However the molecular mechanisms underlying this, is not clear. 
Both estrogen agonists and antagonists are used for clinical purposes in estrogen 
regulation. 
 
1.3.1. Estrogen, Apoptosis and Bcl-2 Family of Proteins 
 
 Estrogen regulates many mechanisms through its target genes as mentioned 
before and apoptosis is one of the major ones. Estrogen has a dual role on apoptosis; 
it can both stimulate and inhibit apoptosis depending on the type of cell. It induces 
apoptosis in osteoclasts but inhibits in nerve cells, endothelial cells, and epithelial 
cells (Spyridopoulos et al, 1997; Jo et al, 1993). The mechanism of estrogen on 
apoptosis is through the induction of glutathione, Bcl-2 protein, nitric oxide, 
inhibition of inflammatory cytokine production, and directly as an antioxidant 
molecule at the biochemical level (Kobayashi et al, 1997).  
It was noted that apoptotic gradient and Bcl-2 protein which is anti-apoptotic 
were negatively correlated in the presence of estrogen, attracting the attention to Bcl-
2 for estrogen regulation. Estrogen differentially regulates several pro-apoptotic and 
anti-apoptotic members of the Bcl-2 family of proteins. It increases Bcl-2 protein 
expression which has several putative estrogen responsive sites, whereas it decreases 
Bax expression which makes dimers with Bcl-2. This results in the increase in 
proliferation and decrease in apoptosis, promoting cell survival (Alkayed et al, 
2001). Another anti-apoptotic family member Bcl-xL has putative ERE and estrogen 
increases its expression as well. It is not clear though whether estrogen acts directly 
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or indirectly on these molecules but Bcl-2 family of proteins have a crucial role in 
apoptotic regulation of estrogen (Bynoe et al, 2000; Pike, 1999).   
 
1.3.2. Estrogen Effects on Osteocytes and MSCs 
 
Among the target tissues and organs of estrogen, bone marrow is one of the 
most studied ones. It is known that osteoblasts, osteocytes, osteoclasts, bone marrow 
stromal cells, T cells, B cells and most other cells in human and mouse bone marrow 
besides MSCs, express both ERα and ERβ (Weitzmann and Pacifici, 2006; Komm et 
al, 1988). Gender, age, and cell type are important determinants of ER isoform 
expression in the bone marrow. It is known that estrogen stimulates osteoblast 
differentiation, increases bone marrow proliferation, and is involved in the decrease 
of apoptosis in osteoblasts. Also it is found that there is an increase in osteocyte 
apoptosis directly or indirectly in ovx animals and the addition of estrogen decreases 
the apoptosis rate (Tomkinson et al, 1998) In addition, there is an increase in the 
proliferation rate and ovariectomization decreases proliferation while the addition of 
estrogen reverses this effect (Fowler et al, 2005). In MSCs, estrogen increases the 
proliferation rate, reduces apoptosis, upregulates ERα expression, and downregulates 
ERβ expression which is thought to be a repressor (Zhou et al, 2001). The exact 
mechanism which estrogen exerts these effects is not known but osteocyte apoptosis 
is found to be reversely correlated with the skeletal distribution of Bcl-2 protein 
(Stevens et al, 2000; Tomkinson et al, 1998). This suggests that the proliferative and 
anti-apoptotic effect of estrogen on osteocytes and MSCs might be through the 
expression of the Bcl-2 family of pro-apoptotic and anti-apoptotic proteins.  
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2. AIM OF STUDY 
 
MSCs are potential therapeutic agents which are applicable in tissue 
engineering, gene delivery, carry high potential for regenerative medicine and do not 
induce any immune reaction. Besides being a future promise for many disease 
treatments, there are also some handicaps in their applications. Since MSC number is 
very low in vivo, it is important to obtain a certain number of MSCs for their use. 
The proliferation rate and number of MSCs have to be effectively increased in the 
shortest time period in order for MSCs to be adequate for therapeutic regiments. Our 
aim is to examine the role of estrogen for obtaining MSCs in a short period of time. 
We also attempt to understand the mechanism of the action of estrogen. 
 It is known that apoptosis is among the main regulatory mechanisms in all 
organisms and is a conserved system which emphasizes its importance throughout 
evolution. The members of the Bcl-2 family of proteins are strong candidates in the 
regulation of MSC since some of the family members have estrogen receptors, and 
most of them are affected by estrogen evidenced by the presence of putative EREs. 
In addition, Bcl-2 proteins are among the most important families which serve both 
as death agonist and antagonists and have a crucial role in apoptotic balance. This 
makes them potential candidates in the regulation of MSCs. Bcl-2 family members 
can be manipulated in order to obtain more MSC in a shorter time with higher 
proliferative capacity and efficiency. 
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3.   MATERIALS AND METHODS 
 
3.1. Animals and Their Treatments 
 
3.1.1. The Maintenance of the Animals 
 
Adult female Spraque Dawley rats were used for the experiments. The 
animals were kept in the animal holding facility of the Department of Molecular 
Biology and Genetics at Bilkent University under controlled conditions at 22o C with 
12 hour light and 12 hour dark cycles. They were provided with unlimited access of 
food and water. Our experimental procedures have been approved by the animal 
ethical committee of Bilkent University (Bil-AEC 2005/2)  
 
3.1.2. Ovariectomization of the Animals 
 
 Animals were anesthesized with Ketamin (Ketalar, Park Davis) 
subcutaneously at a dose of 30mg/kg. The dorsal part was shaved with a razor, and 
was immobilized. After fully anesthesized, 2 cm of incision were made on both sides 
of the vertebrate, fat pads were removed to reach the ovaries. Ovaries at the tip of 
each uteri horn were tied with silk and then removed. Then the remaining fat pads 
were put back into their location and the skin of the animal was sutured with 
absorbex 4.0 (75 cm). After the operation the animals were put under a lamp to keep 
them warm. Animals were kept under supervision until they fully recovered from the 
anesthesia. Ovx animals were used approximately after 2 months after the operation 
to ensure the total deprivation of estrogen from their bodies. Each time an ovx animal 
was sacrificed by cervical dislocation, another female rat of the same age which has 
not been operated was also sacrificed and called the “normal” group of animal.  
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3.1.3. Isolation of the Bone Marrow from the Animals 
 
After the animals were sacrificed by cervical dislocation for the isolation of 
the bone marrow, the gastrocnemius and biceps regions were shaved with a razor. 
Then the femur and tibia were removed, and the ends of bones were cut and flushed 
with DMEM (Biochrom FG 0435) which contains 10% Fetal Bovine Serum 
(Biochrom-S0115) and 1% penicillin/streptomycin solution (Biochrom-A2213), by 
using a 5ml syringe (Figure 3.1). The mixed media and bone marrow were 
centrifuged at 4000 rpm for 3 min in order precipitate the cells of the bone marrow. 
Then the media was removed and the cells were washed three times with 1X PBS 
buffer to prepare for tissue culturing.       
 
 
Figure 3.1 The isolation of the bone marrow of the rats 
 
 3.2. Cell Culture 
 
 3.2.1. Cell Number Detection with Cell Count 
 
After the heterogenous bone marrow cells was washed and precipitated, they 
were suspended in 10 ml of MesenCult media and the mixture was micropipetted 
into a hemocytometer. The number of cells in the chamber was determined by 
counting under the light microscope. The cell number was calculated according to 
the following formula:  
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concentration of cells in original mixture = 
 
       (http://en.wikipedia.org/wiki/Hemocytometer) 
 
3.2.2. MSC Culture 
 
MSCs were cultured by MesenCult media (Stem Cell technologies) with 
supplement (Stem Cell Technologies), and 1% penicillin/streptomycin solution 
(Biochrom-A2213). Next day, the media of the tissue culture plates were changed 
and the majority of the non-adherent cells were removed. The media of the cells were 
changed in every 4-5 days, after washing with sterile 1X PBS prior to the change. 
The adherent cells on the 14th day of the cell culture were mostly MSCs but on the 9th 
day there were also adherent cells which were not MSCs particularly.   
 
3.2.3. Estrogen Treatment 
 
For the estrogen treatment of cells, 17 ß-estradiol (Sigma) was used, which 
will be referred to as “estrogen” in the following sections. The cells which will be 
treated with estrogen were cultured with MesenCult media at first, without estrogen. 
At every media change including the first day, estrogen was added to the media of 
the cells at a physiological concentration of 10-7 M (Zhou et al, 2001).     
 
3.3. Standard Solutions and Buffers 
 
DEPC-Treated ddH2O  
1ml DEPC 
1lt ddH2O 
Stirred in a hood for 1 hour, autoclaved in order to inactivate the DEPC 
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10x PBS 
80 g NaCl 
2 g KCl 
8,01g Na2HPO4.2H2O 
2g KH2PO4 
1 liter ddH2O pH: 7,2 
Working solution (1XPBS) was prepared by diluting 10XPBS by 10 times 
 
50X TAE Buffer 
2M Tris Base (242 g) 
57,1 ml Glacial Acetic Acid 
50mM EDTA 
Add to 1 lt by ddH2O  
Working solution (1XTAE) prepared by diluting 50XTAE by 50 times 
 
10 X Agarose Gel Loading Dye 
0,009g BFB 
0,009g XC 
2,8mL ddH2O 
1,2ml 0,5M EDTA. 
Total volume brought to 15ml by adding glycerol, dilute 1:10 in sample prior 
to loading to electrophoresis gel 
 
5M NaOH 
10g NaOH  
50ml ddH2O. 
 
4% PFA 
4g PFA  
100ml 1XPBS  
Dissolved by heating, solution prepared freshly 
 
5M NaCl 
292.2g NaCl  
1lt ddH2O. 
 
10%SDS 
100g SDS  
1lt ddH2O 
 
1M Tris 
60.55g Tris  
300ml ddH2O 
21ml 37% HCl 
pH adjusted to 8.0 with HCl, total volume brought to 500ml by adding 
ddH2O. 
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0.5M EDTA 
93.05g EDTA  
300ml ddH2O 
pH adjusted to 8.0 with NaOH, total volume brought to 500ml by adding 
ddH2O. 
 
30% Acrylamide Mix 
145g Acrylamide  
5g bis-acrylamide 
500ml ddH2O 
Filtered, stored in dark at 40C. 
 
SDS-PAGE Running Buffer (5X stock solution) 
15g Tris 
73,2g Glycine 
5g SDS 
1lt ddH2O 
1X working solution prepared by diluting the 5X SDS-PAGE running buffer 
5 times, stored at 40C  
 
Bradford Reagent 
100 mg Coomassie Brilliant Blue G-250  
100 ml 85%phosphoric acid 
50 ml 95%EtOH 
850 ml ddH2O 
Filtered through Whatman no:1 
 
Lysis Buffer 
150 mM NaCl 
500 mM Tris pH:8 
1% NP-40 
4% Protease Inhibitor Cocktail 
 
10X TBS 
12.19 g Tris 
87,76 g NaCl 
pH adjusted to 8, total volume brought to 1lt by adding ddH2O 
 
1X TBS-T 0,5% 
50 ml 10X TBS 
450 ml ddH2O 
2,5 ml Tween-20 
Total volume brought to 500ml by adding ddH2O 
 
Blocking Solution for Western Blot (5%) 
2,5 g milk powder 
50mL 1X TBS-T 
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Blocking Solution for Immunofluorescent Staining 
1% BSA 
3 ml 1XPBS 
15 µl tween-20 
 
Cracking Buffer (2X Protein Loading Buffer) 
50mM Tris HCl pH: 6,8 
2mM EDTA pH: 6,8 
1% SDS 
20% Glycerol 
0,02% BFB 
Add 1% ß-mercaptoethanol prior to use 
 
Coomassie Blue Staining Solution: 
0,25 g coomassie brilliant blue 
45 ml Methanol 
45 ml ddH2O 
10 ml glacial acetic acid 
 
5X Running Buffer 
15 g Tris base 
72 g Glycine 
5 g SDS 
1 liter ddH2O 
Diluted to 1X prior to use 
 
Semi-dry Transfer Buffer 
2,5 g glycine 
5,8 g Tris base 
0,37 g SDS 
200 ml methanol 
800 ml ddH2O 
 
Destaining Solution 
100 ml methanol 
35 ml acetic acid 
365 ml ddH2O 
 
Permeabilisation solution 
0,1 g sodium acetate 
100µl Triton X-100 
100 ml ddH2O 
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3.4. MSC Count 
 
On the 9th and 14th days of the cell culture, the cells were washed with 1X 
PBS buffer twice and trypsinized (0,25 % trypsin-EDTA solution; Sigma) for 5 
minutes at 370C. 10ml of MesenCult media was added to trypsinized cells and they 
were counted on hemocytometer.  
 
3.5. Colony Forming Assay 
 
MSCs were washed with 1X PBS, then they were air dried. MetOH was used 
for fixation and left for 5 minutes. Then the cells were washed again with 1X PBS 
buffer and giemsa staining reagent (Carlo Erba code: 453616) was added and left for 
5 min. The reaction of giemsa staining was stopped by the addition of tap water and 
at the end the colonies were dyed in purple.    
 
3.6. Determination of the Gene Expression 
 
3.6.1. Total RNA Isolation from the MSCs  
 
On the 9th and 14th days of the cell culture, total RNAs from the MSCs were 
isolated. The cells were first washed with 1X PBS buffer in order to eliminate the 
non-adherent cells in the media. Then the cells were trypsinized and incubated at 
37oC for 5 min. MesenCult media was added to the trypsinized cells and centrifuged 
at 1500 rpm for 5 min. Then the media was removed and the precipitated cells were 
washed with cold 1X PBS buffer and centrifuged again at 1500rpm for 5 min. Next 
the 1X PBS buffer was removed and the total mRNA was isolated from the 
precipitate by using RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
protocol. The RNA isolated was stored at -80oC.    
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3.6.2. Concentration and Integrity of RNA 
 
1 µl of the total RNA samples were diluted in a ratio of 1:500 with DEPC-
treated ddH2O. Then the OD measurements were taken at 260 and 280 nm 
wavelengths with the spectrophotometer (Beckman, California, USA). The O.D.260/ 
O.D.280 ratios were calculated in order to determine if there is a phenol, protein or 
DNA contamination in the RNA samples.  The expected values are between 1,6-2,0. 
Then agarose gel electrophoresis was performed to check the integrity of the isolated 
RNAs. 1% agarose gel was prepared with 1X TAE buffer and 30 ng/ml ethidium 
bromide solution which was added to visualize the RNA. The samples were prepared 
by adding 1µl of Agarose Gel Loading Dye, 3µl RNA sample and 6µl DEPC-treated 
H2O and were kept at 65 oC for 10 minutes in order to denature the RNA. Then all 
the samples were loaded to the agarose gel and the gel was run at 100V for 30 
minutes. It was visualized under the transilluminator (Bio-Rad, California, USA) and 
MultiAnalyst (Bio-Rad, California, USA) software was used in order to take the 
photographs of the gels. 
   
3.6.3. cDNA Synthesis and PCR 
 
3.6.3.1. cDNA Synthesis  
 
The cDNAs were synthesized from the total RNA samples with the 
RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas, Ontario, Canada) 
according to the manufacturer's protocol. 2µg RNA was mixed with 1µl of oligo(dT) 
primer and ddH2O to a total volume of 12 µl. They were incubated at 70 0C for 5 
minutes and then chilled on ice. Then 4µl of 5x reaction buffer, 1µl of Ribonuclease 
inhibitor, and 2 µl of 10 mM dNTP mix were added to the mixture and incubated at 
37 0C for 5 minutes. Finally, 1 µl of RevertAid MuLV reverse transcriptase was 
added and the mixture was incubated at 42 0 C for 60 minutes. The reactions were 
stopped by heating at 70 0C for 10 minutes, and the mixture was put on ice. The 
cDNAs were stored at -20 0C. 
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3.6.3.2. PCR 
 
3.6.3.2.1. Primer Design 
 
Primers were designed for gapdh, bcl-2, bcl-xL , bax, and  bak. The cDNA 
sequences of the rat homologues of these genes are available at the GenBank 
database. The GenBank Accession numbers of the rat homologues of bcl-2 is 
NM_016993; bcl-xL is U34963, bax is U49729, and gapdh is X02231. For bak, the 
cDNA sequences of mouse and human homologues were aligned by Blast (NCBI), 
and primers were chosen from the largest conserved regions by preferring the mouse 
sequence in the points of mismatches. The mice homologue bak (Y13231) and 
human homologue bak (U23765) were used (Table 3.1). 
 
Table 3.1 The sequences and the sizes of the primers used 
  
gapdh 
(210 bp) 
Forward 
Reverse 
:5’-CCTCCTCATTGACCTCAACTAC -3’ 
:5’-CATGGTGGTGAAGACGCCAG-3’ 
bcl-2 
(584 bp) 
Forward 
Reverse 
: 5’-CCTGGCATCTTCTCCTTC-3’ 
:5’-TGCTGACCTCACTTGTGG-3’ 
bcl-xL 
(346 bp) 
Forward 
Reverse 
:5’-TCAATGGCAACCCTTCCTGG-3’ 
:5’-ATCCGACTCACCAATACCTG-3’ 
bax 
(578 bp) 
Forward 
Reverse 
:5’-AATCATGGACGGGTCC-3’ 
:5’- GCCCATCTTCTTCCAG-3’ 
bak 
(536 bp) 
Forward 
Reverse 
:5’-CCGGAATTCCAGGACACAGAGGA-3’ 
:5’-CCAAGCTTGCCCAACAGAACCAC-3’ 
 
 
3.6.3.2.2. Semi-Quantitative PCR 
 
  In order to compare the mRNA expression levels of the samples, 
semiquantitative PCR were performed and gapdh was used as a control for equal 
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loading. The cycle number of the RT-PCR reactions of the bcl-2 family members, 
were optimized in order to detect the expression levels before saturation. In all 
reactions ddH2O was added instead of cDNA to the negative control groups. 
Quantification of the amplicon intensities was performed using MultiAnalyst 
software. The quantitated values for the bcl-2 family members were normalized with 
the quantitated values for the gapdh for each sample separately. And the resulting 
graphs were drawn by these normalized values. The reaction ingredients used in PCR 
reactions are shown in Table 3.2 and the conditions of different PCR reactions are 
shown in Figure 3.2. 
 
Table 3.2 The reaction mixture used in PCRs  
 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction Ingredients Volume 
cDNA  1 µl 
10X Taq Buffer (MBI Fermentas, Ontario, Canada) 2,5 µl (1X) 
25 mM MgCl2 solution ((MBI Fermentas) 1,5 µl (1,5mM) 
Forward Primer (Invitrogen)  1 µl (10 pmol) 
Reverse Primer (Invitrogen) 1 µl (10 pmol) 
2 mM dNTP (MBI Fermentas)  2,5 µl (0,2mM) 
Taq Polymerase (MBI Fermentas, Ontario, Canada) 0,2 µl (1U)  
ddH2O 15,3 µl 
Total 25 µl 
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        gapdh PCR 
 
 
 
 
         
        bcl-2 PCR 
 
 
 
 
         
        bak PCR 
 
 
 
 
 
        bax PCR 
 
 
 
 
 
        bcl-xL PCR 
 
 
Figure 3.2 The cycle numbers and conditions of the PCRs 
 
     Denaturation 5 min at 94oC 
 
30 sec. at 95 oC 
 30 sec. at 60 oC                    28 cycles 
 30 sec. at 72 oC 
 
      Extension: 10 min. at 72 oC 
     Denaturation 5 min at 94oC 
 
30 sec. at 95 oC 
 30 sec. at 55 oC                    27 cycles 
 30 sec. at 55 oC 
 
      Extension: 10 min. at 72 oC 
     Denaturation 5 min at 94oC 
 
30 sec. at 95 oC 
 30 sec. at 55 oC                    30 cycles 
 30 sec. at 72 oC 
 
      Extension: 10 min. at 72 oC 
     Denaturation 5 min at 95oC 
 
45 sec. at 94 oC 
 40 sec. at 59 oC                    35 cycles 
 40 sec. at 72 oC 
 
      Extension: 10 min. at 72 oC 
     Denaturation 5 min at 94oC 
 
30 sec. at 95 oC 
 30 sec. at 52 oC                    33 cycles 
 30 sec. at 72 oC 
 
      Extension: 10 min. at 72 oC 
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3.6.3.3. Agarose Gel Electrophoresis 
 
1% agarose gel was prepared with 1X TAE Buffer and 30 ng/ml ethidium 
bromide solution. Samples were prepared by addition of 1µl Agarose Gel Loading 
Dye to 10µl of cDNA sample and loaded to the agarose gel. The gel was run at 120V 
for 30 minutes and visualized under transilluminator (Bio-Rad, California, USA). 
MultiAnalyst (Bio-Rad, California, USA) software was used to take photographs of 
the gels and compare the cDNA band intensities for semi-quantitative analysis. The 
gene Ruler DNA Ladder Mix (Fermentas, #SM0331) was used as a marker and 5µl 
was loaded to every gel.  
 
3.7. Protein Expression 
 
3.7.1. Total Protein Isolation from the MSCs 
 
The total protein of the MSCs were isolated on the 9th and 14th days of the 
cell culture. The cells were washed with 1X PBS buffer twice in order to wash out 
the non adherent cells. Then the cells were scraped with a scraper and put into a 15 
ml falcon tube. Then the mixture was centrifuged at 1500 rpm for 5 minutes. The 
1XPBS was removed and the precipitate was suspended in lysis buffer which was 
prepared freshly as described in section 3.3 and checked against any protein 
contamination with Bradford reagent prior to use. The mixture was left on ice for 30 
min and mixed gently every 5 -10 minutes. Then the mixture was centrifuged at 
13000 rpm for 20 minutes. The supernatant which contained the proteins was taken 
to a separate eppendorf tube. It was first dipped into liquid nitrogen for a few 
seconds and then stored at -800C. 
  
3.7.2. Protein Quantification 
 
Protein quantification was made with Bradford assay. A standard curve was 
made by using 6 different BSA concentrations as in Table 3.3. 
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Table 3.3 The standards used for the derivation of the standard curve for 
protein concentration detection 
 
 
 
 
 
 
A standard curve was formed by measuring the different BSA concentrations 
at a fixed wavelength of 595 nm. A formula was derived from the graph derived by 
putting the O.D. measurements to the y axis and BSA amount to the x axis. Then a 
second set of measurements was made by taking the lysis buffer sample containing 
900µl Bradford reagent+98µl 0,15 M NaCl+2µl lysis buffer as blank. The other 
samples contained 900µl Bradford reagent+98µl 0,15 M NaCl+2µl protein sample 
and was measured at 595 nm fixed wavelength as well. The O.D. measurements were 
put to the formula derived from the standard BSA concentrations, and the 
concentrations of the proteins were derived.  
 
3.7.3. Western Blotting 
 
3.7.3.1. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
The protein samples were separated by SDS-PAGE gel with 10% resolution 
gel, and 5% stacking gel. The proteins were loaded with a concentration of 20ng for 
Bcl-2 and Bak experiments and 40ng for Bax and Bcl-xL experiments. A total 
volume of 20 µl was loaded to the gel which contained the protein, 1% cracking 
buffer containing 10% ß-mercaptoethanol, and ddH2O. The samples were left at 700C 
for 10 minutes and then they were put on ice for 5 minutes. In each experiment, all 
protein samples were loaded in equal concentrations in order to compare the protein 
expressions between the groups. The PageRuler Prestained Protein Ladder (MBI 
Fermentas, Ontario, Canada) was used as a protein molecular weight marker and 5µl 
was loaded for each gel. The gel was run at 80 volts in 1X cold running buffer until 
Standards Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 
BSA(1µg/µl) 0 µl 2,5 µl 5 µl 7,5 µl  10 µl  12,5 µl  
0,15 M NaCl 100 µl 97,5 µl 95 µl 92,5 µl 90 µl 87,5 µl 
Bradford 
Reagent 
900 µl 900 µl 900 µl 900 µl 900 µl 900 µl 
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the proteins passed from the stacking gel to the resolution gel. Then the gel was run 
at 120 volts until the dyes reached the end of the glass and was stopped. The gel was 
removed from between the glasses. After the stacking part of the gel was removed 
and washed with dH2O, it was put in the semi-dry transfer buffer. 
 
3.7.3.2. Transfer of Proteins to the Membrane 
 
The proteins were transferred onto the membrane by semi-dry transfer since 
our proteins are within the range of 20kDa-30kDa and semi-dry transfer method is 
the best for small proteins. 4 Whatman papers (no.1), and the resolution part of the 
SDS-PAGE gel which are at the sizes of 5,5 cm to 8,5cm were left in the semi-dry 
transfer buffer for 10 minutes. The membrane was left in MetOH for 30 seconds, in 
dH2O for 2 minutes, and then in semi-dry transfer buffer for 10 minutes. Then two of 
the Whatman papers, the membrane, the gel, and 2 more Whatman papers were put 
on to the semi-dry transfer apparat (Biorad) in this order. The bubbles between the 
layers were removed and the transfer was made at 0,16 Ampere for 50 minutes. After 
the transfer was completed, the membrane was washed 5 minutes with 1X TBS-T 
buffer before the proteins were immunologically detected. 
 
3.7.3.3. Immunological Detection of Immobilized Proteins 
 
After washing, the membrane was left in the blocking solution for 1 hour at 
RT on an orbital shaker. Then primary antibodies of Bcl-xL (H-5 sc-8392 Santa Cruz 
Biotechnologies), Bak (G-23 sc-832 Santa Cruz Biotechnologies), Bax (P-19 sc-526 
Santa Cruz Biotechnologies), or Bcl-2 (N-19 sc-492 Santa Cruz Biotechnologies) 
were prepared in block solution at a concentration of 1:500 and was left overnight at 
4oC. The following day the membrane was washed with 1X TBS-T 4 times 5 minutes 
each and incubated with the secondary antibody of Anti-Rabbit-HRP (Sigma, 
Montana, USA) at a concentration of 1:2500 for 1 hour at RT on an orbital shaker. 
Then the membrane was washed again 4 times, 5 minutes each. ECL Plus Detection 
Reagent (Amersham Biosciences, New Jersey, USA) was added on to the membrane 
and left for 5 minutes. The excess detection reagent was drained off, the membrane 
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was placed on glass, and covered with stretch film. The wrapped glass was placed in 
a x-ray film cassette. Films were exposed to x-ray for between 15-30 minutes 
depending on the intensity of the protein expressions. After exposure, the films were 
developed.  
    
3.7.3.4. Coomassie Blue Staining of the Gel and Membrane  
 
The gel was stained with coomassie blue staining solution to confirm that the 
transfer is successful, and contains equal amount of protein. The membrane and gel 
were left in the staining solution for 5 min, and then they were left in destaining 
solution overnight, by changing the solution on the membrane and gel each time the 
colour of the destaining solution turned into blue.   
 
3.7.4. Immunofluorescent Staining 
 
The cells were grown on cover slips (Deckglaser 100 No.1 12mm) in the cell 
culture plates. The plates were taken from the 37oC incubator and the media was 
removed. The cells were washed twice with 1X PBS and fixed with MetOH by 
incubating for 7 minutes. Then the cells were washed again with 1X PBS twice and 
left in 3% H2O2 for 15 minutes. After washing twice with 1X PBS, the cells were left 
in blocking solution for 30 minutes at RT. After the completion of the blocking step, 
the cells were incubated with Bcl-xL antibody (H-5 sc-8392 Santa Cruz 
Biotechnologies) at a concentration of 1:100, or Bak antibody (G-23 sc-832 Santa 
Cruz Biotechnologies) at a concentration of 1:100, or Bax antibody (P-19 sc-526 
Santa Cruz Biotechnologies) at a concentration of 1:100, or Bcl-2 (N-19 sc-492 
Santa Cruz Biotechnologies) with a concentration of 1:100, or CD90 antibody 
(Chemicon-MAB1406) at a concentration of 1:500. The samples were left in the 
antibody solution for 16 hours at 4oC. The sides of the plates were covered with 
parafilm in order to prevent evaporation. The next day the cells were taken and 
washed with 1X PBS twice. The secondary antibodies of Anti-Rabbit-FITC (Sigma) 
with 1:200 dilution for Bak, Bax, and Bcl-xL antibodies, and Anti-Mouse-FITC 
(Sigma-F2012-1ML) with 1:100 dilution for Bcl-2 antibody in block solution were 
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added and incubated for 1 hour at RT in the dark. After the secondary incubation, the 
cells were washed twice with 1XPBS and DAPI (Roche-10236276001) was added to 
the slides. After 10 minutes the DAPI staining was washed and the cover slips 
containing the cells were put on slides with glycerol. The pictures of the slides were 
taken with the fluorescent microscope (Axio Cam Zeiss) with a total magnification 
of 400X. The excitation wavelength of FITC was 490nm and the excitation 
wavelength for DAPI filter was 359nm. After their pictures were taken, the samples 
were stored in the dark at 4oC.   
    
3.8. In Situ Cell Death Detection (TUNEL ASSAY) 
   
DNA fragmentation was detected in situ by TdT- (terminal deoxynucleotidyl 
transferase) mediated fluorescein-dUTP labeling kit (Roche Diagnostics, Mannheim, 
Germany). Cells adherent to the cover slips washed with 1X PBS twice and were 
fixed in freshly prepared 4% paraformaldehyde in PBS for 1 hour at room 
temperature. Then the cells were washed with 1X PBS for 3 times and incubated 
with a freshly prepared permeabilisation solution (0.1 % Triton X-100, 0.1 % sodium 
citrate) for two minutes on ice. Then the cells were washed again with 1X PBS twice, 
and 50 µl of TUNEL reaction mixture was added onto each sample and incubated for 
one hour at 370C in the dark in a humidified chamber. The samples were washed 
with 1XPBS and were left in DAPI solution for 10 minutes in dark. Then they were 
washed again with 1XPBS and put on slides with glycerol. Slides were then analyzed 
by fluorescent microscopy. For evaluation by the fluorescent microscopy, we used an 
excitation wavelength in the range of 450-500 nm and detection in the range of 515-
565 nm. As negative control, we incubated the slides in the absence of terminal 
deoxynucleotidyl transferase. For positive controls, the samples were first treated for 
10 minutes with DNaseI (Fermentas- EN0521) at a concentration of 0,4u/µl at RT to 
induce DNA strand breaks prior to labeling procedures, and then incubated with 50 
µl of TUNEL reaction mixture. The samples were kept at dark at 40C. 
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4.    RESULTS 
 
  
All the experiments were performed with two animal groups: adult female 
rats (normal group), and ovariectomized adult female rats (ovx group). Cells from 
both the normal and ovx groups were cultured in the presence and absence of 
estrogen. The physiological concentration of estrogen used in our experiments was 
10-7 M, which is widely accepted in literature (Zhou et al, 2001). All the experiments 
were performed on the 9th day and 14th day of the cell culture. MSCs fully mature, 
and become ready to differentiate on the 14th day of the cell culture. On the other 
hand, we also included 9th day of cultures where MSCs have not fully matured, are 
not ready to differentiate, are in the process of forming colonies, and many other 
single cells adherent to the culture plate are present in the tissue culture besides 
MSCs. Due to this reason the majority of the cells adherent to the surface of the plate 
on the 14th day of culture were considered as MSCs, while only the colonies forming 
on the 9th day of the culture were considered as MSCs as evidenced by the 
immunostaining with the MSC markers. 
      
 4.1. Effect of Estrogen on the Number of MSCs 
  
In order to examine the effect of estrogen on the number of MSCs, the cells 
of the normal and ovx groups treated with and without estrogen were counted. The 
cells were trypsinized and counted on the 9th and 14th days of the tissue culture. Since 
the cells were washed twice before counting them, the non-adherent cells were 
washed away and only the adherent cells were counted (Table 4.1).  
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Table 4.1 Cell counts on the 9th day and 14th days of the cell culture Both the 
number of cells, and the ratio of the 14th day cells compared to the 9th day cells in the 
same treatment type are seen.  
 
 
 
 
 
 
 
 
Table 4.2 The ratio of estrogen treated cells to the non-treated cells on the 9th 
day and 14th day cultures  
 
 
 
On the 9th day of the culture, our results showed that the addition of estrogen 
increased the number of adherent cells in the normal group. The number of the cells 
in the estrogen treated group was 1,55 times more compared to the group that had not 
been treated with estrogen. On the other hand in the ovx group the number of cells 
did not increase with estrogen treatment. (Figure 4.1, Table 4.2).    
 
 
 
 
 
 
            
 
  
 
 
 Normal Normal+estrogen Ovx Ovx+estrogen 
9th day 318,750 495,000 116,250 116,250 
14th day 348,750 551,250 97,500 163,200 
Normal+estrogen/normal ratio  Ovx+estrogen/ovx ratio 
9th day 1,55 1 
14th day 1,58 1,67 
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Figure 4.1 Cell number comparisons of the 9th day cell cultures 
The number of cells counted in the normal, normal+estrogen, ovx, and ovx+estrogen 
groups are shown by bars. 
 
 
 However on the 14th day of the cell culture, we found that estrogen treatment 
increased the number of cells both in the ovx and in the normal group. In the normal 
group the cell number of estrogen treated cells was 1,58 times more than the group 
without any treatment, and in the ovx group the estrogen treated cells were 1,67 
times more than the group without any treatment (Figure 4.1, Table 4.2). 
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Figure 4.2 Cell number comparisons of the 14th day cell cultures  
The number of cells counted in the normal, normal+estrogen, ovx, and ovx+estrogen 
groups are shown by bars. 
 
 These results indicate that the treatment of both the normal and ovx groups 
with estrogen increases the number of cells on the 14th day, and the normal group 
number on the 9th day. Estrogen also affects the rate of cell number increase form the 
9th day to the 14th day of the cell culture, in both the normal and ovx groups. 
 
4.2. Colony Forming Assay 
 
 Colony forming is one of the distinguishing characteristics of the MSCs. In  
order to see whether the increase in the cell number of the estrogen treated groups are 
also seen in the colony numbers, colony forming assay was performed in the groups 
treated with and without estrogen on the 9th and the 14th days of the cell culture. At 
least two samples from each normal and ovx group treated with and without estrogen 
were taken, and the colonies were counted (Table 4.3). Then the average number of 
colonies among each group was calculated and the results were compared among the 
9th day groups (Figure 4.3) and 14th day groups (Figure 4.4) 
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Table 4.3 Average number of colonies counted on the 9th and 14th day culture 
groups treated with and without estrogen   
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Figure 4.3 The number of colonies on the 9th day of the cell culture 
The colonies counted were compared among the 9th day normal, normal+estrogen 
treated, ovx, and ovx+estrogen treated groups. 
 
 Normal Normal+estrogen Ovx Ovx+estrogen 
9th day 16 35 12,5 23 
14th day 38,5 45 32,5 33 
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Figure 4.4 The number of colonies on the 14th day of the cell culture  
The colonies counted were compared among the 14th day normal, normal+estrogen 
treated, ovx, and ovx+estrogen treated groups. 
 
On the 9th day of the cell culture, there were very few colonies compared to 
that of the 14th day. However the addition of estrogen to the culture media, increased 
the number of colonies approximately two fold both in the normal group and in the 
ovx group. This suggests that using estrogen enables MSCs to form colonies much  
more efficiently. 
On the 14th day of the cell culture the estrogen treatment of the normal and 
ovx groups also increased the number of colonies formed (Figure 4.5, Figure 4.6), 
but to a lesser degree compared to the rate of increase in the 9th day results. These 
results indicate that estrogen is more effective in the process of MSC colonies being 
formed. The increase in the number of colonies in both the 9th day and 14th day cell 
culture groups with the addition of estrogen, are in parallel with the cell count 
results.   
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A)      B) 
  
             14th day normal cells         14th day normal+estrogen cells 
Figure 4.5 Normal and normal+estrogen treated MSC colonies on the 14th day 
of cell culture The big pictures are viewed with a light microscope with a 
magnification of 400X and the small pictures are viewed with a magnification of 
100x in order to see a more detailed profile of the colonies formed A) 14th day 
colonies formed by normal cells. B) 14th day colonies formed by normal cells treated 
with estrogen.  
 
 
A) B) 
   
  14th day ovx cells                        14th day ovx+estrogen cells 
Figure 4.6 Ovx and ovx+estrogen treated MSC colonies on the 14th day of cell 
culture  
The big pictures are viewed with a light microscope with a magnification of 400X 
and the small pictures are viewed with a magnification of 100X in order to see a 
more detailed profile of the colonies formed A) 14th day colonies formed by ovx cells 
B) 14th day colonies formed by ovx cells treated with estrogen 
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 4.3. Apoptotic Rate of MSCs 
 
Since both the number of cells and CFUs have increased by the addition of 
estrogen to the culture media in both the normal and ovx groups, a possible 
explanation was explored for the mechanism of this increase. One possibility was the 
involvement of the apoptotic pathway since estrogen plays a major role in the 
apoptotic mechanism of several systems. The MSC groups described in section 4 
were checked for the presence of apoptotic cells by the TUNEL assay. We expected 
to see a decrease in the number of apoptotic cells in the groups cultured with 
estrogen. The apoptotic cells were counted by using the fluorescent microscope. The 
FITC filter with an excitation wavelength of 490nm was used to count the apoptotic 
cells, and the ratio of these cells to the total number of cells were calculated by 
counting the total number of cells with the DAPI filter with an excitation wavelength 
of 359nm (Figure 4.7). 
DAPI 
 
 
 
FITC 
Figure 4.7 A sample colony from the TUNEL assay. The total number of cells 
were counted with the DAPI filter, the apoptotic cells were detected with the FITC 
filter. The fluorescence microscope pictures are taken with a magnification of 400X 
MERGED 
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 At least two samples from each group treated with and without estrogen were 
counted for both their total number of cells and apoptotic cells on the 9th and the 14th 
days. Then the ratios of apoptotic cells to total cells were calculated and their 
averages were taken. The results were compared among the 9th and 14th days of the 
cell culture (Figure 4.8 and Figure 4.9). While the cells were being counted, only the 
colonies were considered in order to be sure that the cells counted were MSCs.    
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Figure 4.8 The apoptotic cell ratios on the 9th day cell culture  
The apoptotic cell ratios of the ovx and normal groups treated with and without 
estrogen on the 9th day are compared in the figure. The number of TUNEL positive 
cells were divided to the total number of colonies. 
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Figure 4.9 The apoptotic cell ratios on the 14th day cell culture  
The apoptotic cell ratios of the ovx and normal groups treated with and without 
estrogen on the 14th day are compared in the figure. The number of TUNEL positive 
cells were divided to the total number of colonies 
 
 
Our results showed that both on the 9th day and 14th day of cultures, the rate 
of apoptotic cells have decreased with the addition of estrogen in the normal and ovx 
groups. This decrease is more evident in the 9th day groups. The number of apoptotic 
cells in the estrogen treated groups, are almost half the ratio of the cells without any 
estrogen treatment. These results are parallel with the colony numbers from the CFU 
assay in which the increase in the number of colonies were approximately two-fold 
in the estrogen treated groups on the 9th day of the cell culture. Considering that only 
MSC colonies were counted in both experiments, throughout the formation of MSC 
colonies estrogen increases the proliferation rate and formation of colonies while 
decreasing the apoptotic rate. Estrogen is effective on the 14th day cell culture by 
increasing the colony numbers and decreasing the apoptotic rates, but it is more 
effective on the 9th day cultures. 
The correlation between the decrease of the apoptotic rates of MSCs with the 
increase in the colonies with estrogen treatment, suggests that estrogen regulates the 
number of MSCs through the apoptotic pathway. The most commonly studied 
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regulators of apoptosis which are also affected by estrogen are the bcl-2 family of 
genes. Due to this reason, the effects of estrogen on the expressions of the bcl-2 
family of genes were examined in order to see the whether they are a part of this 
regulation mechanism of MSCs.  
 
4.4. Gene Expression 
 
The expressions of the bcl-2 family of genes were investigated both at the 
mRNA and the protein level. Among the members of the bcl-2 family of genes; two 
anti-apoptotic genes; bcl-2 and bcl-xL, in addition to two pro-apoptotic genes; bak and 
bax were chosen as candidates in the regulation of MSCs. These genes are the most 
intensively studied bcl-2 family members in mammals and are shown to have ERE. 
They also have been shown to dimerize in the mammalian systems.     
 
4.4.1. Expression of the bcl-2 gene family in MSC Maintenance 
 
4.4.1.1. mRNA Isolation and RT-PCR 
 
The total RNAs of the normal and ovx groups treated with and without 
estrogen were isolated on the 9th and 14th days of the cell culture in order to detect 
the expression levels of the candidate
 
genes bak, bax, bcl-xL, and bcl-2. The 
concentrations of the total RNAs were measured with the spectrophotometer, and the 
mRNAs were run on agarose gel in order to check their intensity and purity (Figure 
4.10 A). Then cDNAs were synthesized, and the expressions of bak, bax, bcl-xL,  
bcl-2 genes were examined with PCR. PCR conditions were optimized before 
performing further experiments with normal group samples (Figure 4.10 B-E).    
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A)   B)    C)     D)        E)        F) 
      
mRNA      gapdh                bcl-2                 bax                     bak                  bcl-xL     
 
Figure 4.10 The isolation of mRNA and the optimization of PCR cycles  
A) In pure mRNA; the 28S, 14S, and 5S bands are observed without any smear. The 
RNAs isolated all gave clear bands and the measurements of the spectrometer was 
confirmed by the gel picture. B) The PCR product of gapdh, 210 bp C) The PCR 
product of bcl-2, 584 bp D) The PCR product of bax, 578 bp E) The PCR product of 
bcl-xL, 346 bp 
 
4.4.1.2. Semi-Quantitative PCR 
 
After the optimization of the cycles, PCR was performed with the normal and 
ovx groups with and without estrogen treatment on the 9th and 14th days of the cell 
culture, by using primers for gapdh, bax, bcl-2, bak, and bcl-xL. PCR results of the 
bcl-2 gene family were normalized according to the gapdh PCRs (Figure 4.11). 
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Figure 4.11 The agarose gel picture of the PCR products of the bcl-2 family of 
genes For the semi-quantitative analysis of the genes, the expression of the bcl-2 
family of genes on the 9th and 14th day in normal, normal+estrogen, ovx (o), and 
ovx+estrogen (oe) groups were selected for each set of cDNAs and evaluated     
 
Every set was normalized within itself for the evaluation of the gene 
expression results. After the normalization was made, the 9th day normal values and 
14th day normal values were considered as 1 and the ratios of all the other treatment 
groups were taken according to the normal values of the 9th day and 14th day. This 
was made to have a standard in the averages, and to evaluate the decrease and 
increase in the ratios depending on estrogen treatments over the standard 1. The 
standard deviations were also calculated and the expression results were compared 
within each gene both on the 9th day (Figure 4.12) and on the 14th day (Figure 4.13).  
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Figure 4.12 The expression graphs of bcl-2 family of genes on the 9th day cell 
culture groups A) The expression profile of bcl-2 B)The expression profile of bcl-xL 
C) The expression profile of bak
 
D)The expression profile of bax 
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Figure 4.13 The expression graphs of bcl-2 family of genes on the 14th day cell 
culture groups A) The expression profile of bcl-2 B)The expression profile of bcl-xL 
C) The expression profile of bak
 
D)The expression profile of bax 
 
Bcl-2 gene expression, which is an anti-apoptotic gene, has increased in the 
normal and ovx groups on the 9th day with the addition of estrogen (Figure 4.12A). 
The expression of the bcl-xL gene has slightly increased with the addition of estrogen 
on the 9th day in the normal group but has slightly decreased in the ovx group (Figure 
4.12B). The expression of bak, which is a pro-apoptotic gene, has decreased with the 
addition of estrogen on the 9th day normal and ovx groups (Figure 4.12C). However 
bax, which is also a pro-apoptotic gene, has decreased with the addition of estrogen 
in both the normal and in the ovx groups on the 9th day (Figure 4.12D). On the 14th 
day, estrogen has decreased the expression of the bcl-2 gene both in the normal and 
ovx groups (Figure 4.13A). The expression of bcl-xL has decreased in the normal 
group and there was an increase in the ovx group with estrogen treatment on the 14th 
day (Figure 4.13B). Bak expression has increased with the addition of estrogen on 
the 14th day normal and ovx groups (Figure 4.13C). Also the addition of estrogen has 
increased the expression of the bax gene in the normal and ovx group similar to bak 
on the 14th day (Figure 4.13D). Although the decreases and increases in the gene 
expressions are noted by comparing the ratio bars, when the standard deviations are 
considered, these oscillations are not very crucial in the overall gene expression 
profiles. This suggests that there is no transcriptional regulation in MSCs by 
estrogen. 
 
4.4.2. Expression of Bcl-2 family of Proteins  
 
4.4.2.1. Immunofluorescent Staining (IF) 
  
We first performed IF to check the presence of Bcl-2 family of proteins on 
the 9th and 14th days of normal, normal+estrogen, ovx, and ovx+estrogen groups of 
MSC cultures (Figure 4.14-4.17). In addition to the Bcl-2 family of proteins, CD90 
expression was checked in order to confirm that the cells and colonies are MSC 
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colonies, since CD90 is a MSC marker (Figure 4.18). Negative controls, in which no 
primary antibody was added, were included in each group both on the 9th and the 14th 
day to confirm the specifity of the antibodies (Figure 4.19). Our IF results showed 
that, all of the Bcl-2 family of proteins that were tested were present in all groups of 
the 9th and 14th day cell cultures. We also confirmed that these cells were MSCs by 
detecting the CD90 expression in these colonies. 
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Figure 4.14 Expression of Bcl-2 on 9th day and 14th day culture groups 
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Figure 4.15 Expression of Bcl-xL on 9th day and 14th day culture groups 
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Figure 4.16 Expression of Bak on 9th day and 14th day culture groups 
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Figure 4.17 Expression of Bax on 9th day and 14th day culture groups 
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DAPI 
 
 
 
FITC 
Figure 4.18 CD90 expression in MSC colonies Total magnification of 400X 
DAPI 
 
 
 
FITC 
Figure 4.19 Negative sample of MSC colonies Total magnification of 400X 
 
MERGED 
MERGED 
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 4.4.2.2. Western Blot 
 
  We performed western blot analysis in order to quantify the protein 
expressions that were shown in the IF assays. Proteins isolated from normal, 
normal+estrogen, ovx, and ovx+estrogen groups of the 9th and 14th day of the 
culture were loaded to the SDS-PAGE gel and were evaluated separately. Western 
blot was performed by using antibodies against Bcl-2, Bak, Bax, and Bcl-xL. 
Loadings were controlled by staining the membrane with coomassie blue staining 
after the membranes were developed.  
Our results showed that on the 9th day of the culture, the expression of Bcl-2 
was approximately the same in the normal group with the addition of estrogen but in 
the ovx group the expression of Bcl-2 has decreased with the addition of estrogen 
(Figure 4.20). On the other hand Bcl-xL expression was the same with the addition 
of estrogen both in the normal group and ovx group on the 9th day of cell culture 
(Figure 4.21). Bak has increased in the normal group of the 9th day with estrogen 
treatment but was approximately the same in the ovx group (Figure 4.22). The 
expression of Bax has increased both in the normal and ovx group with the addition 
of estrogen (Figure 4.23). Our data on the expression of Bcl-2 family of proteins on 
the 9th day of MSC culture with and without estrogen treatment did not reveal a 
correlation as we expected. This might be due to other cells and their signals 
interfering with MSCs, or the difference in the signals throughout the formation 
period of the MSC colonies.     
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Figure 4.20 Bcl-2 expression on the 9th day of cell culture  
A) Western blot results of the Bcl-2 protein expression on the 9th day n, n+e, ovx, 
ovx+e groups B) Equal loading of 20ng of protein from 9th day groups  
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Figure 4.21 Bcl-xL expression on the 9th day of cell culture  
A) Western blot results of the Bcl-xL protein expression on the 9th day n, n+e, ovx, 
ovx+e groups B) Equal loading of 40ng of protein from 9th day groups 
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Figure 4.22 Bak expression on the 9th day of cell culture  
A) Western blot results of the Bak protein expression on the 9th day n, n+e, ovx, 
ovx+e groups B) Equal loading of 20ng of protein from 9th day groups 
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Figure 4.23 Bax expression on the 9th day of cell culture  
A) Western blot results of the Bax protein expression on the 9th day n, n+e, ovx, 
ovx+e groups B) Equal loading of 40ng of protein from 9th day groups  
 
On the 14th day of cell culture, we observed an expression pattern of the Bcl-2 
family of proteins that supported our hypothesis. Among these proteins, the 
expressions of Bcl-2 and Bcl-xL, have increased when the MSCs were cultured with 
estrogen in the normal groups (Figure 4.24, 4.25). This suggests that these genes are 
candidates for increasing the proliferation and decreasing the apoptotic rate in 
MSCs. In addition the expression of Bak, decreases with the addition of estrogen in 
the normal group (Figure 4.26). This result also assigns a role as a candidate gene in 
MSC regulation. In the ovx groups; Bak expression decreases (Figure 4.26) and Bcl-
xL decreases with the addition of estrogen (Figure 4.25) which is in correlation with 
their normal groups. However, Bcl-2 protein expression decreases in the ovx group 
A) 
B) 
B) 
A) 
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with the addition of estrogen on the 14th day, but since the ovx group is deprived of 
estrogen for a certain period, this might affect the estrogen susceptibility. Bax 
expression on the other hand has not changed much in the normal group and has 
increased in the ovx group with estrogen treatment (Figure 4.27). These results 
suggest that Bcl-2, Bcl-xL, and Bak are potential candidates for the regulation of 
MSCs by estrogen, while Bax is not affected by estrogen in our system as expected, 
so it is not considered as a candidate gene in MSC regulation. 
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Figure 4.24 Bcl-2 expression on the 14th day of cell culture  
A) Western blot results of the Bcl-2 protein expression on the 14th day n, n+e, ovx, 
ovx+e groups B) Equal loading of 20ng of protein from 14th day groups  
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Figure 4.25 Bcl-xL expression on the 14th day of cell culture 
A) Western blot results of the Bcl-xL protein expression on the 14th day n, n+e, ovx, 
ovx+e groups B) Equal loading of 40ng of protein from 14th day groups 
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Figure 4.26 Bak expression on the 14th day of cell culture  
A) Western blot results of the Bak protein expression on the 14th day n, n+e, ovx, 
ovx+e groups B) Equal loading of 20ng of protein from 14th day groups   
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Figure 4.27 Bax expression on the 14th day of cell culture 
A) Western blot results of the Bax protein expression on the 14th day n, n+e, ovx, 
ovx+e  groups B) Equal loading of 40ng of protein from 14th day groups  
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5. DISCUSSION 
 
Stem cells are the new hope for the century since they have the potential to 
differentiate to several types of cells and tissues. They are future candidates for 
many therapeutic applications and can be the cure for many diseases such as 
neurodegenerative diseases, diabetes, and cancer (Fuchs and Segre, 2000). MSCs 
are ASCs which can differentiate to osteoblasts, chondrocytes, adipocytes, 
myocytes, cartilage, tendon, muscle, ad fat tissue (Baksh et al, 2004; Caplan and 
Bruder, 2001). One of the major issues is that they form a very small population of 
nucleated cells in the bone marrow and their number has to be increased before they 
can be used for therapeutic purposes. There are several factors increasing cellular 
proliferation, and estrogen is one of them.  
Estrogen regulates many pathways vital for the homeostasis of the body and its 
loss or decrease results in serious health problems such as osteoporosis, 
arteriosclerosis, increase in coronary heart diseases and neurodegenerative diseases. 
It has also been shown that estrogen reduces apoptosis when apoptosis is induced, 
and increases the proliferation rate in MSCs in other systems (Zhou et al, 2001).  
Apoptosis is a conserved mechanism throughout evolution and any disruption 
in the apoptotic pathway results in severe problems such as neurodegenerative 
diseases, cancer, autoimmune disorders, and viral infections. Mitochondrion is one 
of the key regulators of the apoptotic pathway and cytochrome c is one of the most 
important apoptotic factors which activate the caspase cascade. When cytochrome c 
is released, it leads to apoptosis and the members of the bcl-2 family of genes are 
the main molecules that regulate its release from the mitochondria. Estrogen 
differentially affects the expression of bcl-2 family members. It increases Bcl-2 and 
Bcl-xL expression which are anti-apoptotic members whereas it decreases Bax and 
Bak expression (Alkayed et al, 2001). It is not clear though whether estrogen affects 
the bcl-2 family of genes directly or indirectly, but estrogen is crucial in the 
regulation of their expression (Dubal et al, 1999; Pike, 1999).  
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The effect of estrogen on the bcl-2 family of genes and MSC cell proliferation 
makes apoptosis a strong candidate in MSC maintenance. Therefore our main aim 
was to find out the effects of estrogen on MSC maintenance, that is on the 
proliferation rate and apoptosis. We also hypothesize that estrogen regulates the 
expression of bcl-2 family of genes and this controls apoptosis. 
In order to reach our aim we took the following approach; bone marrow cells 
were isolated and cultured for 14 days with MSC media. According to this protocol, 
culturing for 14 days makes these cells ready for differentiation. However we 
performed all our experiments on day 9 and day 14 of the cell culture. The reason is 
that the 9th day was considered as a step in the process of MSC colony formation 
and we wanted to check the regulation throughout the formation of MSCs. It is also 
important to note that there is not any well-defined marker to identify MSCs in the 
bone marrow cells at the time of isolation. 9th day cell cultures contain not only 
MSCs but also other adherent fibroblastic cells. Therefore, in the experiments where 
all cells are isolated such as cell counting, mRNA expression, and Western blot on 
the 9th day cell cultures, we can not rule out the possibility of other adherent single 
cells interfering with the results. The cells on the 14th day, however, are mainly 
composed of MSC colonies and the data obtained from the 14th day culture give a 
more accurate picture regarding to the nature of MSCs. 
In order to detect the effect of estrogen on MSC number, the adherent cells in 
the tissue culture were counted on the 9th day and 14th days of the tissue culture. On 
the 14th day, estrogen increased the number of both the normal and ovx group which 
suggests that estrogen has an effect on MSC number both in estrogen deprived 
conditions, which is the ovx group, and the normal group. On the 9th day, estrogen 
treatment increased the number of the normal cells but the ovx group was not 
affected by estrogen. This might indicate that in the process of MSC formation, cells 
from ovx animals are not affected by estrogen since they are deprived of estrogen 
completely for at least 2 months. A 9 day period might not be enough for them to 
increase their proliferation rate since their estrogen level was almost zero for a long 
time. On the other hand, normal cells on the 9th day were more susceptible to the 
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effects of estrogen since they have a basal amount of estrogen and it is easier for 
them to increase their proliferation rate. Also it should be considered that other types 
of cells in addition to MSCs are isolated on the 9th day due to other single cells 
adherent to the culture plate existed on the 9th day, so they might affect the numbers 
counted, since all the cells in the cell culture plate have to be isolated for cell 
counting.  
To see if the increasing number of cells are MSCs, colony forming assay was 
made on the 9th and 14th days. Although on the 9th day there were only a few 
colonies with few number of cells, it was observed that both on the 9th day and the 
14th day the colony number increased with the addition of estrogen both in the 
normal and ovx groups. In some samples the colony number of the normal group 
treated with estrogen increased compared to the untreated group on the 14th day. On 
the 9th day ovx group only, the addition of estrogen did not seem to affect the cell 
number, but there was an increase in the colony number, suggesting the induction of 
MSC formation. Also it is possible that estrogen increased the MSC cell number but 
since there were other cells in the culture, the increase in MSCs could not be seen in 
the total cell number increase. In general these results were in correlation with the 
cell numbers counted, so we can conclude that estrogen increases the MSC number 
and the colonies it forms throughout MSC maintenance. These results are also in 
accordance with Zhou et al, 2001, which has shown that MSCs increase in number 
with estrogen treatment. 
To check estrogen’s role in MSCs maintenance, we examined the effect of 
estrogen in the apoptotic rates of MSC by in situ cell death assay. When the ratios of 
apoptotic cells to total cells in the colonies were compared, both on the 9th day and 
14th day cell cultures, the addition of estrogen decreased the death ratios in the 
normal and ovx groups. Especially on the 9th day the apoptotic decrease rates were 
the same as the increase on the 9th day colony forming rates, this suggested that 
estrogen is effective in the process of MSC colony formation both by increasing 
proliferation and decreasing apoptosis.  It is important to note that in our system, we 
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did not induce apoptosis with any factor. Therefore our apoptotic rate of 10% seems 
to be the physiological effect of estrogen on MSCs.  
It is observed that the 9th day cell culture colonies are more susceptible to 
estrogen and the number of colonies increase with a higher rate compared to the 14th 
day cell cultures. Similarly the apoptotic rates decrease with a higher rate in the 9th 
day culture cells compared to the 14th day culture cells with the addition of estrogen. 
On the 9th day MSCs are in a tendency of increasing their number and on the 14th 
day they are ready to differentiate to other cell types, suggesting that MSCs perform 
more symmetrical divisions throughout the process of colony forming on the 9th day 
and more asymmetrical divisions on the 14th day cell cultures. From these results, it 
is tempting to speculate that estrogen has a more profound affect on symmetrical 
divisions and is less effective in the process of asymmetrical division in MSC 
maintenance. The correlation between these is a future aspect to be checked.  
After analyzing the effect of estrogen on MSC proliferation and apoptosis, the 
next step was to see whether this was via the bcl-2 family of genes. First of all the 
gene expressions of bcl-2, bcl-xL, bak, and bax  were checked on the mRNA level. 
All groups expressed the bcl-2 family of genes both on the 9th day and on the 14th 
day in variable levels. The average of at least 3 different groups were taken for 
semi-quantitative PCR analysis, and although there were slight oscillations in the 
gene expression levels on different days and groups, when the standard deviations 
were considered, the increases and decreases were not very significant. This 
suggested that the bcl-2 family of genes were expressed but they were not affected 
much by estrogen on the transcriptional level. 
In addition to the mRNA expression profile of bcl-2 family of genes, we also 
examined the expression of Bcl-2, Bcl-xL, Bak, Bax  proteins on the groups treated 
with and without estrogen. In the IF experiments all the groups both on the 9th and 
14th days of the cell culture expressed these proteins so western blot was performed 
to quantitate their expression levels. The 9th day was again used as a group to see the 
expression profile throughout the formation of MSCs but our main aim was to see 
the 14th day cell culture results in which MSCs have fully formed. Our western blot 
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results showed that all the proteins were differentially expressed in all groups both 
on the 9th and 14th days of the cell culture. However we did not observe a stable 
pattern of expression where anti-apoptotic members increased and pro-apoptotic 
members decreased with estrogen addition on the 9th day. During the isolation of 
both mRNAs and proteins on the 9th day, many other cells adherent to the tissue 
culture which were not MSCs were isolated together with MSCs as mentioned 
before. The signals from the other cells might have affected the protein and gene 
expression, so the results are not very dependable. The 14th day expressions were 
more dependable and important since the majority of the cells were MSCs.  
On the 14th day cell culture, the normal + estrogen expressions of Bcl-2, and 
Bcl-xL which are anti-apoptotic members of the bcl-2 family of genes, have 
increased compared to the normal expressions, while the expression of Bak which is 
a pro-apoptotic member has decreased with the addition of estrogen. The addition of 
estrogen had a similar affect on the ovx group compared to the normal group in the 
Bcl-xL and Bak expressions on the 14th day culture. The Bcl-2 protein expression 
did not increase in the ovx group on the 14th day, which might be because of the loss 
of estrogen susceptibility due to a long period in an estrogen deprived environment. 
The expression of our 4th candidate protein Bax, was approximately the same with 
or without the addition of estrogen in the normal groups, and has increased in the 
ovx group with the addition of estrogen. Bax, different from the other candidate 
members, is cytosolic and does not go to the mitochondria unless apoptosis is 
induced. In our experiments there was no stimulus to induce apoptosis, so Bax 
might be present in the cells but not active (Wolter et al, 1997). In cases of 
starvation or other stresses, the expression levels of Bax might be different (Zhu et 
al, 2006). As a result; Bcl-2, Bcl-xL, and Bak seem to be strong candidates of the 
Bcl-2 family of proteins which are affected by estrogen on the translational level in 
MSC regulation, and estrogen might be regulating the apoptotic and proliferative 
activity by increasing the level of Bcl-2 and Bcl-xL proteins whereas decreasing the 
level of Bak. Since the Bcl-2 family of proteins function as homo- and heterodimers, 
these results suggest that these anti-apoptotic and pro-apoptotic candidates might be 
forming dimers among themselves. These results are in correlation with other 
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studies performed on other stem cells like skin stem cells, HSCs, and epithelial stem 
cells where apoptosis and some members of the bcl-2 family of genes are shown to 
be important in the differentiation and regulation pathways (Potten et al, 1997; 
Polakowska et al, 2005; Domen et al, 2000). 
The reason for observing differential expression at the protein level but not at 
the mRNA level might be post-transcriptional and transcriptional modifications on 
the bcl-2 family of genes such as phosphorylation, dephosphorylation, dimerization, 
translocation, cleavage, chromatin remodeling, etc. (Tsujimoto and Shimizu, 2000). 
These may be caused either by estrogen or other regulatory pathways.   
The effect of estrogen on some other genes has also been studied in MSCs 
such as BMP-2, ALP, type I collagen, cbfa1, and TGFβ-1 on the mRNA level. 
These are mostly osteogenic markers and the addition of estrogen has increased the 
expression of those genes both in the normal and ovx groups, suggesting that 
estrogen might have a role not only in the decrease of apoptosis and increase in 
proliferation, but also differentiation and osteogenic potential (Zhou et al, 2001). It 
should be noted though, that these results are at the transcriptional level and the 
protein expressions should also be checked because they might not be parallel to 
mRNA results as in our experiments. These results might be important in the 
treatment of osteoporosis and bone fractures.   
In general we can conclude that apoptosis is one of the main regulatory 
mechanisms in the maintenance and proliferation rate of MSCs. Bcl-2, Bak, and 
Bcl-xL are strong candidates in this regulation and estrogen affects the expression 
rates of these proteins, increasing the colonies and decreasing the apoptotic rate. 
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6. FUTURE STUDIES 
 
 Further studies can be made on the regulation of bcl-2 family of genes on 
MSC maintenance and proliferation. Our candidate genes bcl-xL, bcl-2, and bak can 
both be silenced and over expressed in order to confirm that the regulation of 
estrogen is via these genes. If the MSC colony numbers change according to the 
silencing and over expression of these genes, this might suggest that with estrogen 
treatment the anti-apoptotic candidate genes can be increased and MSC number can 
become sufficient for treatments. Our lab is performing these experiments. In 
addition, the differentiation capacity of the MSCs obtained by the over expression of 
anti-apoptotic genes or silencing of the pro-apoptotic genes can be tested to see 
whether the efficiency and differentiation potential has changed or not. Other than 
Bcl-2 family members, the effects of estrogen on ERα and ERβ expressions in 
MSCs can also be tested in addition to the Bcl-2 family of proteins. In other studies 
it has been shown that estrogen has an effect of ER expressions in the bone marrow 
and MSCs, so the coordination of the ER expressions with the Bcl-2 family of 
proteins can be tested (Zhou et al, 2001). 
 Since we hypothesize that our candidate genes are regulated on the 
translational level, the possible mechanisms behind this regulation might be studied 
in detail. If estrogen does not change the expressions of these genes on the mRNA 
level significantly, there might be post-transcriptional modifications effecting the 
protein expressions. These possible modifications can be studied and checked on 
whether they are effective in the expression of bcl-2 family of genes in the presence 
and absence of estrogen. 
 Besides the expressions of the members of bcl-2 family of genes, the 
expressions of upstream and downstream molecules can be checked. For example 
the tumor suppressor p53 gene can be checked which is known to be a regulator of 
bcl-2 and bax both in vitro and in vivo (Miyashita et al, 1994). Also the expressions 
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of the downstream molecules of the bcl-2 family of genes might be checked such as 
initiator and effector caspases.  
  The MSC number in cell cultures can be increased for a higher efficiency in 
the experiments. The main problem especially on the 9th day experiments was 
having very few colonies with small number of cells, and unidentified single cells 
being also adherent to the plate. Therefore especially in the colony forming assay, IF 
experiment, and TUNEL assay, only the colonies were considered as MSCs but it 
was not possible to eliminate the other cells. Due to this reason the 9th day 
experiments and results were not dependable in these experiments. There is no 
marker to identify MSC in vivo, the markers which MSCs express are common with 
the other cells adhering to the plates such as fibroblasts and due to this reason are 
not very helpful in their selection. Specific markers such as cd90 are not expressed 
in MSCs until 4 or 5 days have passed after culturing them, so it is really difficult to 
plate pure MSCs at the very beginning of the cell culture. Maybe with dynabeads 
HSCs, with negative selection HSCs can be removed at the very beginning of the 
cell culture by using specific markers. Purifying MSC at the very beginning would 
increase the preciseness of the experiments.  
Also the effects of estrogen on MSC number and its efficiency in treatment 
should be tested in vivo. The MSCs, in which the anti-apoptotic genes are 
overexpressed and pro-apoptotic genes are silenced, can be labeled and injected to 
rats. Since MSCs help in the forming of bone and muscle cells, the rats which have 
muscle injuries, and bone fractures might be used to find out the differences 
between the recovery rates and the contribution of the injected MSCs to the injury 
sites compared to the control groups. This can be done both in normal and ovx 
animals.      
In addition to the effects of estrogen, the effects of estrogen antagonists such 
as tamoxifen, raloxifene, and ICI can be tested both in normal and ovx groups in the 
presence and absence of estrogen in order to see the changes in expression. Some 
antagonists also act like agonists depending on the presence of absence of estrogen 
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so these effects can also be observed to see if a higher yield of cells can be obtained 
with these combinations.  
 Other experimental conditions and their affects on MSC efficiency with 
estrogen addition can be observed by testing the effect of isolating MSCs at 
different passage numbers since it is known that passaging MSCs changes their 
differentiation potential. In addition MSCs isolated from different sources such as 
adipose tissue can be tested to see if their efficiency is the same as the ones isolated 
from the bone marrow. 
 In general if the increase of MSC number can be accomplished in vitro and 
in vivo in shorter time periods, it would be very useful for MSC based treatments. 
The best way to accomplish this is to figure out the mechanism which regulates their 
proliferation and interfere with it in order to increase this rate. Although further 
studies have to be done and the results have to be confirmed, the apoptotic pathway 
and especially some members of the bcl-2 family of genes seem to be strong 
candidates in the regulatory pathway which can be manipulated by estrogen 
treatment.   
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